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Abstract 
Understanding of the biology and clinical behavior of ductal carcinoma in situ (DCIS) is 
currently inadequate. The aim of this comprehensive review was to identify important mo-
lecular biological markers associated with DCIS and candidate markers associated with in-
creased risk of ipsilateral recurrence after diagnosis of DCIS. A comprehensive systematic 
review was performed to identify studies published in the past 10 years that investigated bi-
ological markers in DCIS. To be included in this review, studies that investigated the rate of 
biological expression of markers had to report on at least 30 patients; studies that analyzed 
the recurrence risk associated with biomarker expression had to report on at least 50 pa-
tients. There were 6,252 patients altogether in our review. Biological markers evaluated in-
cluded steroid receptors, proliferation markers, cell cycle regulation and apoptotic markers, 
angiogenesis-related proteins, epidermal growth factor receptor family receptors, extracel-
lular matrix-related proteins, and COX-2. Although the studies in this review provide valuable 
preliminary information regarding the expression and prognostic significance of biomarkers in 
DCIS, common limitations of published studies (case-series, cohort, and case-control studies) 
were that they were limited to small patient cohorts in which the extent of surgery and use of 
radiotherapy or endocrine therapy varied from patient to patient, and variable methods of 
determining biomarker expression. These constraints made it difficult to interpret the ab-
solute effect of expression of various biomarkers on risk of local recurrence. No prospective 
validation studies were identified. As the study of biomarkers are in their relative infancy in 
DCIS compared with invasive breast cancer, key significant prognostic and predictive markers 
associated with invasive breast cancer have not been adequately studied in DCIS. There is a 
critical need for prospective analyses of novel and other known breast cancer molecular 
markers in large cohorts of patient with DCIS to differentiate indolent from aggressive DCIS 
and better tailor the need and extent of current therapies. 
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INTRODUCTION 
A diagnosis of ductal carcinoma in situ (DCIS) of 
the breast was rare before the 1980s; however, with 
the introduction of mammography, the incidence of 
DCIS grew dramatically. Currently, more than 60,000 
patients are diagnosed with DCIS in the United States 
each  year.  For  many  years,  mastectomy  was  the 
standard  procedure  to  treat  DCIS;  however,  since 
DCIS  is  a  noninvasive  and  silent  disease, Journal of Cancer 2011, 2 
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breast-conserving  therapy  with  or  without  radio-
therapy is now considered sufficient and the accepted 
method  to  treat  DCIS.  A  definitive  goal  in  treating 
DCIS is to prevent ipsilateral invasive breast cancer 
recurrence as the mortality associated with a diagno-
sis of pure DCIS is less than 1–2% [1]. About 5-30% of 
patients  with  DCIS  treated  with  breast-conserving 
therapy with or without radiation experience an ipsi-
lateral  local  recurrence,  and  about  half  of  these  re-
currences are invasive. Clinicians are unable to pre-
dict the risk of local recurrence or progression to in-
vasive breast cancer in patients with DCIS following 
their treatment, a major concern that needs to be ad-
dressed. Numerous studies have been conducted to 
address this concern, and in a few studies, investiga-
tors  have  concluded  that  several  histopathologic 
characteristics  of  DCIS—lesion  size,  margin  status, 
nuclear grade, architectural pattern, and presence of 
necrosis—are predictors of recurrence [1]. 
 The U.S. National Cancer Institute has recently 
identified a critical need for investigation and valida-
tion of molecular factors to improve risk stratification 
of patients with DCIS, which will facilitate identifica-
tion of the optimal therapy for each individual patient 
[2]. 
 A molecular biological marker (―biomarker‖) is 
a molecular feature that is objectively measured and 
that serves as an indicator of a normal biological re-
sponse, a pathogenic process, or the likelihood of re-
sponse to an existing or novel pharmacologic therapy. 
In cancer, biomarkers may be used for disease detec-
tion, disease staging, monitoring of disease response 
to therapy, and prediction of patient prognosis [3]. A 
biomarker may be DNA or RNA based or a protein 
marker measured directly in tissues, serum, or other 
body fluids [3]. 
 For DCIS, the optimal biomarker or combination 
of  measured  biomarkers  would  provide  additional 
prognostic information beyond that provided by oth-
er  clinical  and  pathologic  factors  established  in  the 
field as risk factors for local recurrence, such as lesion 
grade, lesion size, patient age, margin status, and use 
versus nonuse of adjuvant radiotherapy. The perfect 
biomarker  or  combination  of  biomarkers  and/or 
clinical pathologic factors would establish which cases 
of  DCIS  were  highly  unlikely  to  ever  be  associated 
with progression to invasive breast cancer and thus 
which patients needed no further therapy. Biomarker 
expression  might  also  be  useful  in  individualizing 
therapy for DCIS with respect to the need for local 
excision versus mastectomy or the need for adjuvant 
radiotherapy. 
 Validation of cancer biomarkers is complex and 
must be thorough if the marker is to be used in patient 
care [4-6]. The aim of this comprehensive review was 
to  identify  important  biomarkers  associated  with 
DCIS  and  candidate  biomarkers  associated  with  in-
creased risk of ipsilateral recurrence after diagnosis of 
DCIS. 
METHODS 
A comprehensive search of the MEDLINE and 
Cochrane  databases  was  performed  on  February  4, 
2011. Search terms included the U.S. National Library 
of Medicine’s Medical Subject Headings ductal carci-
noma in situ, in situ breast cancer, intraductal carcinoma, 
stage  0  breast  cancer,  and  DCIS.  Additional  search 
terms included estrogen receptor, progesterone receptor, 
androgen receptor, Ki-67, cyclin D1, cyclin A, cyclin E, 
p16, p21, p27, p53, Bcl-2, Bax, survivin, c-myc, Rb, VEGF, 
HPR1, HER1, HER2, HER3, HER4, CD10, SPARC and 
COX-2 (Table 1).  A total of 622 studies were identified 
on biological markers in DCIS published in November 
2000 or later. One additional significant study pub-
lished  in  1998  and  referenced  in  other  studies  in-
cluded in the review was also included [7]. The fol-
lowing types of studies were excluded: in vitro stud-
ies; studies involving only animals; case reports; and 
studies reporting on patients with concurrent invasive 
breast cancer or non-breast malignancies. Studies that 
investigated  the  rate  of  biological  expression  of 
markers  had  to  report  on  at  least  30  patients,  and 
studies  that analyzed the  recurrence risk associated 
with biomarker expression had to report on at least 50 
patients. There were 6,252 patients altogether in our 
review. 
RESULTS 
Biomarker expression rates for different catego-
ries of biomarkers and notes on how expression rates 
were derived are presented in Tables 2–8. Information 
on  the  relationship  between  biomarker  expression 
and  the  risk  of  ipsilateral  recurrence  following  sur-
gery for DCIS is presented in Table 9. Table 9 lists the 
year published, the number of patients in the study, 
the  type  of  surgery  performed,  whether 
post-lumpectomy radiotherapy was given, the medi-
an  follow-up  time,  whether  endocrine  therapy  was 
utilized,  and  a  synopsis  of  whether  the  biomarker 
studied was associated with an increased risk of local 
recurrence. 
Steroid Receptors 
Estrogen Receptor 
Estrogen receptor (ER) was one of the first bio-
logical markers to be studied in depth, and today ER 
is one of the most valuable markers in breast cancer. 
ER status in patients with breast cancer predicts re-Journal of Cancer 2011, 2 
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sponse to endocrine therapy. Among the 36 studies in 
our comprehensive review that examined ER expres-
sion rate in DCIS, the mean ER expression rate was 
68.7% (range: 49–96.6%, Table 2). 
 Numerous studies revealed ER expression to be 
inversely  related  to  the  nuclear  grade  of  DCIS:  ER 
expression  was  higher  in  well-differentiated  lesions 
than in poorly differentiated lesions [8-15]. One study 
revealed  that  ER  expression  was  more  common  in 
cribriform  DCIS  than  in  other  DCIS  subtypes  [7]. 
Similarly, another study revealed that ER expression 
was more common in papillary, solid, and cribriform 
DCIS  than  in  micropapillary  and  comedocarcinoma 
DCIS [9]. 
 Many  investigators  studied  the  relationship 
between  ER  and  other  biological  markers.  Several 
studies  revealed  ER  to  be  inversely  correlated  with 
HER-2/neu (HER2) expression [7, 9, 13, 16-18]. One 
study revealed that ER expression was inversely cor-
related  with  p53  expression  [7].  A  few  studies  re-
vealed ER expression to be positively associated with 
high Bcl-2 expression [7, 12, 16]. One study reported a 
significant correlation between ER negativity and cy-
clooxygenase-2 (COX-2) positivity [19]; however, an-
other study did not find a significant correlation be-
tween  ER  and  COX-2  [20].  Kulkarni  et  al  reported 
several significant associations between ER and other 
markers—for  instance,  progesterone  receptor  (PR), 
Cyclin D1, p53, and p21 [21]. Altintas et al reported 
that lesions with high proliferative activity were more 
likely to be ER negative [15]. 
ER Expression and Risk of Local Recurrence 
 We  identified  16  studies  (2,470  total  patients) 
that evaluated the relationship between ER expression 
and risk of local recurrence (Table 9). Four of these 
studies revealed an association between ER-negative 
DCIS and risk of local recurrence [16, 22-24]. In the 
first study, a nested case-control study by Provenzano 
et  al,  the  investigators  compared  53  patients  with 
DCIS  who  had  a  subsequent  local  recurrence  to  42 
age- and date- of-diagnosis-matched control subjects 
with DCIS who did not have a recurrence [22]. Pa-
tients in the series had breast-conserving surgery with 
(n=10) or without adjuvant radiotherapy (n=85). Pa-
tients  with  subsequent  local  recurrence  were  more 
likely  than  those  without  recurrence  to  have 
ER-negative  disease  (62%  vs.  35%;  OR:  0.2; P=0.01, 
Table 9) [22]. 
 In  the  second  study  that  found  a  relationship 
between  ER-negative  DCIS  and  risk  of  local  recur-
rence, another nested case-control study, Kerlikowske 
et al evaluated biomarker expression and risk of local 
recurrence among 329 patients with DCIS who were 
all  treated  with  wide  local  excision  without  subse-
quent radiotherapy. The authors selected tissues to be 
studied  for  biomarker  expression  from  72  women 
who  had  a  subsequent  invasive  cancer  event,  71 
women who had a subsequent DCIS event, and 186 
randomly  selected  women  who  served  as  control 
subjects who did not have a subsequent tumor event 
[24].  This  nested  case-control  study  had  a  median 
follow-up time of 8.2 years. According to the univari-
ate analysis, patients with a subsequent DCIS event 
were  more  likely  than  those  without  a  subsequent 
tumor  event  to  have  ER-negative  disease  (31%  vs. 
20%,  Table  9).  ER-negative  status  was  individually 
associated  with  DCIS  recurrence.  In  addition, 
ER-negative  status  combined  with  either  HER2  ex-
pression  or  Ki-67  expression  was  associated  with 
DCIS recurrence. Similar results were observed in the 
multivariate analysis. Patients with DCIS recurrence 
were  more  likely  to  exhibit  the  phenotype 
ER-HER2+Ki-67+, and this phenotype was a predictor 
of DCIS recurrence (hazard ratio: 5.8; 95% confidence 
interval [CI]: 2.4-14, Table 9). In patients who devel-
oped  a  subsequent  invasive tumor,  the  investigators 
did not find ER to be a predictor of recurrence either 
individually or in combination with other markers in 
a phenotype [24]. This study by Kerlikowske et al is 
one of the largest and arguably one of the most im-
portant studies in the field. This study by Kerlikowske 
et al is valuable because it allows clinicians to study a 
group  of  patients  who  all  underwent  the  identical 
therapy  for  DCIS  -  in  this  case  local  excision  alone 
without  radiotherapy.  Overall,  28%  of  the  patients 
had a local-regional recurrence. This high rate of re-
currence may be related to the fact that 45-61% of pa-
tients in the study had positive margins or uncertain 
margin  status  [24].  Obtaining  definitive  negative 
margins is now a well-known, accepted prerequisite 
for breast-conserving therapy  [1], and this situation 
illustrates the complexity of interpreting results and 
the potential clinical value of these types of biomarker 
studies for present day therapy of DCIS. 
 In the third study that found a relationship be-
tween ER-negative DCIS and risk of local recurrence, 
Roka et al evaluated 132 patients with DCIS treated 
with  breast-conserving  surgery  without  (n=33)  or 
with whole-breast radiotherapy (n=99) and found that 
patients with ER-negative DCIS were more likely than 
those  with  ER-positive  DCIS  to  have  a  local  recur-
rence (12.2% vs. 3.7%, Table 9) [23]. This study pro-
vides clinically useful information in that it gives an 
absolute difference between the rates of local recur-
rence  in  patients  with  ER-negative  and  ER-positive 
DCIS  treated  with  surgery  and  radiotherapy:  about 
8.5%. Journal of Cancer 2011, 2 
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 Ringberg  et  al  investigated  187  patients  with 
DCIS who underwent breast-conserving therapy with 
(n=66) or without (n=121) radiotherapy. In the group 
of patients who did not receive radiotherapy, 31 pa-
tients  had  a  recurrence.  The  authors  used  principal 
components analysis to evaluate a cell biological in-
dex that included ER and PR negativity, overexpres-
sion of HER2, low Bcl-2 expression, accumulation of 
p53,  nondiploidy,  and  high  Ki-67  expression.  Ac-
cording to the multivariate analysis, the combination 
of ER-negative DCIS and the biological markers in the 
index was a strong predictor of local-regional recur-
rence (relative risk: 1.3; 95% CI: 1.0-1.6, Table 9) [16]. 
Zhou  et  al  [25]  examined  the  relationship  be-
tween triple-negative DCIS (negative for ER, PR, and 
HER2; also known as basal-like breast cancer) and risk 
of local recurrence. This study included 392 patients, 
approximately half of whom received adjuvant radi-
otherapy. Of the 392 patients, 42 patients had an in 
situ recurrence, and 34 had an invasive recurrence. The 
authors compared the 32 patients with triple-negative 
DCIS with the 360 patients with other phenotypes and 
found that patients with basal-like DCIS had a higher 
risk of local recurrence. However, this difference did 
not reach statistical significance. This study illustrates 
additional  barriers  to  determining  the  effect  of  bi-
omarker  expression  on  local  recurrence,  including 
small number of patients and inconsistent use of ad-
juvant  treatments  (e.g.,  radiotherapy),  which  can 
confound results. 
ER Expression and Response to Therapy 
A  predictive  biomarker  is  a  marker  that  can 
predict the response to a specific therapy. For invasive 
breast cancer, the presence of ER expression and the 
degree  of  ER  expression  have  unequivocally  been 
shown to predict response to tamoxifen, which blocks 
ER, and aromatase inhibitors, which prevent produc-
tion of estrogen. In women with ER expression, ER 
has  been  demonstrated  to  affect  the  expression  of 
other relevant biomarkers and lead to increased sur-
vival and decreased recurrence risk in women taking 
tamoxifen  or  aromatase  inhibitors  compared  to 
women  not  taking  these  drugs  [26].  In  contrast,  no 
demonstrative  effect  of  tamoxifen  or  aromatase  in-
hibitors is seen in patients whose invasive tumors lack 
ER expression. 
 For DCIS, we found four clinical trials that may 
shed light on the value of ER for predicting response 
to tamoxifen and aromatase inhibitors. The first two 
studies were landmark phase III trials in which pa-
tients  with  DCIS  were  randomized  to  tamoxifen  or 
placebo  after  local  excision  of  DCIS.  The  first,  the 
UK/ANZ DCIS trial, involved 1,701 patients and had 
an unusual randomization scheme involving the use 
of adjuvant tamoxifen and radiotherapy with elective 
decision  to  withhold  or  provide  one  of  these  treat-
ments [27]. The median follow-up time was 12.7 years. 
Although  tamoxifen  significantly  reduced  the  inci-
dence of all new breast events (P<0.0001), the absolute 
differences between rates of new breast cancer events 
in women randomized to tamoxifen and no tamoxifen 
were small. Patients randomized to tamoxifen had a 
3.5% absolute 10-year reduction in the risk of ipsilat-
eral DCIS recurrence, no change in the risk of ipsilat-
eral  invasive  breast  cancer,  and  a  2.3%  absolute 
10-year  reduction  in  the  risk  of  new  contralateral 
breast cancer.  
The second landmark phase III trial was the Na-
tional  Surgical  Adjuvant  Breast  and  Bowel  Project 
(NSABP)  B-24  clinical  trial,  which  included  1,804 
women, and in which tamoxifen was also investigated 
among patients receiving radiotherapy [28]. At a me-
dian follow-up time of 12 years, there were very small 
but statistically significant absolute reductions in rates 
of breast cancer events among patients randomized to 
tamoxifen versus placebo (a 2.4% reduction in the risk 
of  ipsilateral  invasive  breast  cancer  recurrence,  no 
change in the risk of ipsilateral DCIS recurrence, and a 
3.2% reduction in the risk of contralateral breast can-
cer events). An important caveat in interpreting these 
data is that in both the UK/ANZ and NSABP B-24 
trials, patients were not selected to receive tamoxifen 
on the basis of ER positivity. The magnitude of benefit 
might  have  been  higher  if  only  patients  with 
ER-positive  DCIS  had  been  enrolled.  Nevertheless, 
taken together, the results of these two trials suggest 
that ER appears to be a weakly predictive biomarker 
for effecting local recurrence following treatment for 
DCIS. 
 The third pivotal trial implicating ER as a pre-
dictive  biomarker  for  endocrine  manipulation  of 
ER-positive  DCIS  was  reported  by  Chen  et  al  [29]. 
This small study, involving just 23 patients, was un-
dertaken to investigate whether neoadjuvant (admin-
istered before surgery) endocrine therapy resulted in 
detectable histologic alterations. In order to determine 
whether  such  treatment  results  in  detectable  histo-
logic alterations, the authors compared the pathologic 
and biomarker changes in DCIS following neoadju-
vant endocrine therapy (that is, before surgery) to a 
group of patients who did not undergo preoperative 
anti-estrogenic  treatment.  Premenopausal  women 
were  treated  with  tamoxifen,  and  postmenopausal 
women  were  treated  with  letrozole.  Pathologic 
markers of proliferation, inflammation, and apoptosis 
were evaluated at baseline and at 3 months. Following 
treatment,  predominant  morphologic  changes  in-Journal of Cancer 2011, 2 
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cluded increased multinucleated histiocytes and de-
generated cells, a decrease in expression of the prolif-
eration marker Ki-67, and immune infiltration into the 
lesions consistent with a treatment effect. This study 
was significant because of its novel clinical trial de-
sign,  the  so-called  ―window  study  design,‖  which 
allows  investigators  to  test  potentially  promising 
agents  for  DCIS  and  immediately  assess  biological 
response when the patient undergoes surgery [29, 30]. 
 The fourth important trial implicating ER as a 
predictor of response to endocrine therapy was an-
other window study, by Bundred et al. These authors 
randomized  90  postmenopausal  patients  with 
ER-positive DCIS to one of the following treatments 
for 2 weeks before surgery: exemestane, an aromatase 
inhibitor;  celecoxib,  a  COX-2  inhibitor;  exemestane 
and  celecoxib;  or  placebo  [30].  Exemestane  signifi-
cantly reduced proliferation compared with placebo; 
the median reduction was 9%. The effect of exemes-
tane  on  proliferation  was  seen  regardless  of  grade, 
HER2 expression, or PR expression. Celecoxib had no 
effect  on  proliferation  or  apoptosis  either  when  the 
drug was administered alone or when it was admin-
istered in combination with exemestane. Thus, phar-
macologic  endocrine  ablation  with  exemestane  in 
postmenopausal  patients  with  ER-positive  DCIS  re-
sulted  in  a  significant  reduction  in  proliferation  of 
cancer cells in the short term. However, the clinical 
utility  of  aromatase  inhibitors  remains  to  be  deter-
mined from studies to be reported utilizing this class 
of drugs in the adjuvant setting [1]. 
Progesterone Receptor 
PR is considered to be as important as ER in in-
vasive breast cancer. In invasive breast cancer, expres-
sion of PR is weakly prognostic with respect to dis-
ease-free survival and also a predictor of response to 
endocrine therapy. Among the 28 studies in our re-
view that examined PR expression rate in DCIS, the 
mean PR expression rate was 59.6% (range: 40–83.3%, 
Table 2). As with ER, an inverse relationship was ob-
served  between  PR  expression  and  nuclear  grade. 
Patients with high-grade DCIS were less likely than 
patients  with  non-high-grade  DCIS  to  have 
PR-positive disease [8-10, 12, 14, 15]. One study re-
vealed that PR expression was more common in crib-
riform  DCIS  and  noncomedo  DCIS  than  in  other 
subtypes [7]. Another study revealed that PR expres-
sion was more common in papillary, solid, cribriform, 
micropapillary, and comedocarcinoma subtypes than 
in other subtypes [9]. 
 A majority of the studies included in our review 
investigated  the  relationship  between  PR  and  other 
biological markers. A direct positive relationship was 
observed between PR expression and ER expression 
[7, 9, 21]. Also, a positive relationship was observed 
between  PR  expression  and  Bcl-2  expression  [7,  16, 
22]. One study revealed a significant correlation be-
tween PR status and p27 status [31]. Several studies 
reported an inverse relationship between PR expres-
sion and HER2 expression [7, 9, 12, 16, 17, 21]. A few 
studies revealed an inverse relationship between PR 
expression and p53 expression [7, 16]. In addition, an 
inverse  relationship  was  observed  between  PR  ex-
pression and Ki-67 expression [15, 16]. 
 Thirteen studies (2,051 total patients) in our re-
view evaluated the relationship between PR expres-
sion  and  risk  of  recurrence,  and  only  two  of  these 
studies revealed a significant correlation. In a nested 
case-control  study,  Provenzano  et  al  found  that  PR 
negativity was independently associated with risk of 
local-regional  recurrence.  These  authors  compared 
tissues  from  patients  who  subsequently  developed 
ipsilateral recurrence (cases) with those from patients 
who did not develop a recurrence (controls). Patients 
who developed a local-regional recurrence were more 
likely than controls to have PR-negative disease (63% 
vs.  34%,  Table  9)  [22].  As  mentioned  previously, 
Ringberg et al found that a cell biological index that 
included  ER  and  PR  negativity,  overexpression  of 
HER2,  low  Bcl-2  expression,  accumulation  of  p53, 
nondiploidy, and high Ki-67 expression was a strong 
predictor of recurrence [16]. 
Androgen Receptor 
Breast cancer is known to be a hormonally de-
pendent  carcinoma.  Many  immunohistochemical 
studies  conducted  to  date  have  revealed  androgen 
receptor (AR) to be often co-expressed with ER and 
PR in breast tumors, but only a few studies have ex-
amined the role and significance of AR in breast can-
cer etiology and prognosis [32, 33]. Among the four 
studies in our review that examined AR expression 
rate in DCIS, the mean AR expression rate was 65.8% 
(range: 37–81%, Table 2). Hanley et al found that un-
like expression of the other steroid receptors, ER and 
PR,  expression  of  AR  was  slightly  higher  in 
high-grade  DCIS  than  in  non-high-grade  DCIS,  alt-
hough the difference was not significant (93% vs. 89%) 
[8]. Hanley et al studied patterns of co-expression of 
ER and PR with AR. These authors reported that 87% 
of non-high-grade DCIS lesions compared with 30% 
of  high-grade  DCIS  lesions  expressed  both  AR  and 
ER. The co-expression pattern was similar for PR [8]. 
Yu  et  al  reported  similar  findings  with  respect  to 
co-expression  of  AR  with  ER  (P<0.001)  and  PR 
(P=0.035) [33]. 
 There  were  only  two  studies  that  investigated Journal of Cancer 2011, 2 
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the relationship between AR expression and risk of 
recurrence. Provenzano et al found that AR expres-
sion was not a predictor of local recurrence of DCIS 
[22]. Another study that we identified during our ini-
tial search did not meet our selection criteria because 
too few patients were studied; only 34 patients with 
DCIS were investigated [33]. 
Proliferation marker—Ki-67 
Information  on  expression  of  Ki-67  in  DCIS  is 
presented  in  Table  3.  The  nuclear  antigen  Ki-67  is 
commonly  used  to  assess  the  proliferation  rate  of 
breast cancer tumors, which is a key element of pro-
gression of the disease [34]. Our review included 16 
studies that reported Ki-67 expression rates in DCIS 
(Table 3). Barnes et al. reported a median expression 
of Ki-67 in DCIS as 10.9 - 15.5% (Table 3) [35]. Kuerer 
et al reported that the mean (± standard deviation) 
percentage  of  cells  staining  for  Ki-67  was  44.29  ± 
3.42%  (Table  3).  This  expression  rate  is  likely  high 
because  all  the  patients  in  this  series  had 
HER2-positive  DCIS,  and  were  more  likely  to  have 
high-grade lesions [18]. Bundred et al reported that 
the median percentage of cells staining for Ki-67 at 
baseline was 13.5–20.7% in the various subgroups in a 
randomized  trial  of  aromatase-inhibitor  therapy  in 
patients with ER-positive DCIS (Table 3) [30]. 
 A few studies revealed high proliferative activ-
ity to be comedo DCIS than in DCIS with other archi-
tectural patterns [7, 16]. In addition, high proliferative 
activity  was  associated  with  high-grade  versus 
non-high-grade DCIS lesions [12, 16, 36]. 
 Three of the nine studies (1,365 total patients) in 
our  review  that  evaluated  the  relationship  between 
Ki-67 expression and the risk of local recurrence con-
cluded  that  Ki-67  was  not  significantly  associated 
with  disease  recurrence  (Table  9).  The  remaining 
studies  showed  that  Ki-67  was  a  predictor  of  local 
recurrence,  either  independently  or  in  combination 
with other factors. Barnes et al, by means of multi-
variate  analysis,  reported  that  Ki-67  was  an  inde-
pendent predictor of recurrence (Odds ratio: 1.03; 95% 
CI: 1.00-1.06; P=0.038, Table 9). Patients in this study 
who  had  had  a  recurrence  had  significantly  higher 
median proliferative activity than patients who had 
not had a recurrence (15.5% vs. 10.9%, P=0.005) [35]. 
In  a  similar  study  conducted  by  Wilson  et  al,  by 
means of univariate analysis, patients with recurrence 
were more likely to exhibit high proliferative activity 
than  patients  without  recurrence  (71.4  %  vs. 42.2%, 
P=0.006). However, in the multivariate analysis, Ki-67 
was not found to be a predictor of local recurrence.  
[37]. Kerlikowske et al found that high Ki-67 expres-
sion (more than 10% of tumor cells stained) was indi-
vidually  associated  with  recurrence  of  DCIS  in  the 
univariate  analysis,  but,  Ki-67  was  not  individually 
associated with subsequent invasive tumor. However, 
the  phenotype  Ki-67+p16+  and  the  phenotype 
Ki-67+p16+COX-2+ were associated with subsequent 
invasive tumor. Ki-67 was individually associated with 
DCIS  recurrence,  and  the  phenotypes  Ki-67+ER-  , 
Ki-67+p16+, and Ki-67+p16+COX-2+ were also asso-
ciated  with  DCIS  recurrence.  In  the  multivariate 
analysis,  the  Ki-67+p16+COX-2+  phenotype  was  a 
strong  predictor  of  subsequent  invasive  recurrence 
(HR: 2.2; 95% CI: 1.1-4.5, Table 9). Ki-67+p16+COX-2- 
(HR:  3.7;  95%  CI:  1.7-7.9,  Table  9)  and 
ER-HER2+Ki-67+  (HR:  5.8;  95%  CI:  2.4-14,  Table  9) 
were two phenotypes that were strong predictors of 
subsequent DCIS recurrence [24].  
Cell Cycle Regulation and Apoptotic Markers 
Cyclin D1 
Cyclin D1 is one of the many proteins involved 
in cell cycle regulation, specifically regulation of the 
mid-G1  phase.  It  is  also  responsible  for  regulating 
cyclin-dependent kinases [38]. Overexpression of cy-
clin D1 is commonly seen in breast cancer, but it has 
also  been  identified  in  many  other  tumors  [39,  40]. 
Among the six studies in our review that examined 
cyclin D1 expression rate in DCIS, the mean cyclin D1 
expression rate was 55.9% (range: 37–70.6%, Table 4). 
 Oh  et  al  reported  a  significant  correlation  be-
tween cyclin D1 expression and ER expression [41]. 
However, Lebeau et al or Millar et al did not find an 
association between overexpression of cyclin D1 and 
expression of ER and PR [12, 31].  
 In our comprehensive search, we identified five 
studies  (443  total  patients)  that  investigated  the 
prognostic  significance  of  cyclin  D1.  Jirström  et  al 
found cyclin D1 to be strongly and inversely related 
with  ipsilateral  local  recurrence.  Patients  with  low 
cyclin D1 fraction had a higher risk of ipsilateral local 
recurrence than patients with high cyclin D1 fraction 
(32.3% vs. 18.2%, P=0.002, Table 9) [42]. Findings from 
the other four studies indicated no significant corre-
lation  between  cyclin  D1  and  risk  of  local-regional 
recurrence [21, 31, 38, 43]. 
Cyclin A 
Cyclin A, like cyclin D1, is one of the proteins in 
the  cell  cycle  responsible  for  regulating  cy-
clin-dependent  kinases  [38].  We  found  only  two 
studies that investigated the role and significance of 
cyclin A in DCIS. Millar et al reported that 35% of the 
DCIS lesions in their study expressed cyclin A (Table 
4), and Chasle et al did not report an expression rate 
in  their  study.  These  authors  found  no  association Journal of Cancer 2011, 2 
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between cyclin A expression and expression of ER or 
PR or with any histologic features. However, Chasle 
et  al  found  cyclin  A  expression  to  be  significantly 
higher in comedo DCIS than in noncomedo DCIS. In 
the same study, the investigators found cyclin A ex-
pression to be positively correlated with expression of 
two  other  biological  markers,  Ki-67  and  p21  [38]. 
Overall, the investigators did not observe cyclin A to 
be an independent predictor of local-regional recur-
rence; however, when they studied global prolifera-
tion factor, a combination of Ki-67 and cyclin A, they 
found this factor to be correlated with local recurrence 
[38]. 
Cyclin E 
Like cyclin D1 and cyclin A, cyclin E interacts 
with cyclin-dependent kinases in the late-G1 phase of 
the cell cycle [44]. We identified one study that inves-
tigated the relationship between cyclin E expression 
and recurrence in DCIS. Jirström  et al reported that 
approximately 25% of the 92 cases of DCIS in their 
study had high cyclin E expression [42] (Table 9). In 
the same study, the investigators found that cyclin E 
was  not  an  independent  predictor  of  disease  recur-
rence [42]. 
P16 
P16 is a tumor suppressor protein that regulates 
cellular proliferation and growth by acting as a cy-
clin-dependent kinase 4 inhibitor. In the three studies 
we identified that examined p16 expression in DCIS, 
the  mean  p16  expression  rate  in  DCIS  was  33.7% 
(range: 28–39.3%, Table 4). Gauthier et al did not ob-
serve  associations  between  p16  expression  and  any 
histologic factors or hormone receptors [45], and the 
other  two  studies  did  not  look  for  associations  be-
tween p16 expression and other factors.  
We  identified  three  studies  (576  total  patients) 
that investigated the effect of p16 expression on local 
recurrence of DCIS. Jirström et al found that p16 was 
not  an  independent  risk  factor  for  recurrence  [42]. 
Interestingly, Gauthier et al reported that among pa-
tients with high p16 expression and high COX-2 ex-
pression, patients with high proliferative activity were 
more likely to have a local-regional recurrence than 
patients with low proliferative activity [45]. In a fol-
low-up study by the same investigators, Kerlikowske 
et al, by means of univariate analysis, found p16 to be 
the  only  individual  marker  associated  with  subse-
quent invasive recurrence (57% vs. 30%, HR: 2.3, Table 
9). p16 was also associated with subsequent invasive 
recurrence when it was combined with two other bi-
ological  markers,  Ki-67  expression  and  COX-2  ex-
pression.  p16  was  also  associated  with  subsequent 
DCIS  recurrence  when  it  was  combined  with  Ki-67 
expression and lack of COX-2 expression. In the mul-
tivariate  analysis,  the  p16+COX-2+Ki-67+  tri-
ple-positive  phenotype  was  a  strong  predictor  of 
subsequent  invasive  recurrence  (HR:  2.2;  95%  CI: 
1.1-4.5,  Table  9),  and  the  p16+COX-2-Ki-67+ pheno-
type was a predictor of subsequent DCIS recurrence 
(HR: 3.7; 95% CI: 2.4-14, Table 9) [24]. 
P21 
P21 is an important protein that plays a role in 
cell cycle arrest. Studies have shown that p21 can ei-
ther be a downstream target of p53 or can induce cell 
arrest independently of p53 [12, 46]. Among the six 
studies  we  identified  that  examined  p21  expression 
rate in DCIS, the mean p21 expression rate was 53.1% 
(range: 29.6–76%, Table 4). Lebeau et al reported p21 
to be significantly associated with nuclear grade and 
Van  Nuys  prognostic  index;  however,  Oh  et  al  re-
ported  p21-positive  DCIS  to  be  associated  with 
well-differentiated histologic grade [12, 41]. With re-
spect  to  clinicopathological  factors,  Oh  et  al  also 
found that p21 expression was associated with non-
comedo  DCIS  and  tumors  without  necrosis  [41]. 
When Lebeau et al studied the relationship between 
p21 and other biological markers, they found no cor-
relation between p21 expression and p53 expression; 
however, p21 expression was significantly associated 
with expression of epidermal growth factor receptor 
and overexpression of HER2. In addition, p21 expres-
sion  was  correlated  with  cyclin  D1  expression,  but 
only in HER2-positive cases [12]. Kulkarni et al also 
investigated the relationship between p21 and other 
biological markers, and they found that p21 expres-
sion was significantly correlated with ER and cyclin 
D1 positivity [21]. Oh et al found p21 expression to be 
significantly positively correlated with ER expression 
and  significantly  inversely  correlated  with  p53  ex-
pression  [41].  Cornfield  et  al  found  no  correlation 
between p21 and the other biological markers tested 
in their study (ER, PR, HER2, Ki-67, and Bcl-2) [46]. 
 Four studies (365 total patients) in our compre-
hensive search examined the effect of p21 expression 
on local recurrence in DCIS. Only one study identified 
p21  as  an  independent  predictor  of  recurrence. 
Provenzano  et  al  reported  that  patients  with  lo-
cal-regional recurrence were more likely than those 
without recurrence to have p21-positive disease (54% 
vs. 15%, Odds ratio: 6.0; P=0.01, Table 9) [22].  
P27 
P27 is a cyclin-dependent kinase inhibitor, and it 
also plays an important role in growth signaling. In 
recent breast cancer studies, loss of p27 has been as-Journal of Cancer 2011, 2 
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sociated with poor patient outcome [31, 47]. Among 
the  three  studies  in  our  review  that  examined  p27 
expression rate in DCIS, the mean p27 expression rate 
was 56.8% (range: 46.9–68.5%, Table 4). Jirström  et al 
studied the associations between p27 and other bio-
logical markers, and they found p27 expression to be 
significantly  correlated  with  p16  and  cyclin  D1  ex-
pression [42]. Millar et al and Oh et al observed p27 
status  to  be  significantly  associated  with  cyclin  D1 
and ER status [31, 41]. Millar et al also found a signif-
icant  association  between  p27  status  and  PR  status 
[31]. In the same study, no association was observed 
between p27 positivity and cyclin A positivity or be-
tween  cyclin  A  positivity  and  cyclin  D1  positivity. 
Millar et al and Oh et al found no correlation between 
p27  and  clinicopathological  factors  [31,  41].  In  our 
comprehensive  search,  we  found  only  two  studies 
(237 total patients) that investigated the relationship 
between p27 expression and risk of local recurrence in 
DCIS. Both studies showed that p27 was not a pre-
dictor of local recurrence (Table 9). 
P53 
P53, a tumor suppressor gene, is responsible for 
apoptosis  in  the  cell  cycle.  A  mutation  of  p53  can 
compromise its function. P53 mutations are common 
in many cancers and occur in approximately 20% of 
breast carcinomas [43]. Among the 17 studies in our 
review that examined p53 expression rate in DCIS, the 
mean p53 expression rate was 41.4% (range: 11.3–88%, 
Table 4). Two studies revealed p53 expression to be 
more  likely  in  DCIS  of  comedo  type  [7,  48].  Other 
studies showed p53 expression to be correlated with 
high tumor grade [36, 48]. Hieken et al also found that 
p53  was  significantly  associated  with  tumor  grade 
and the presence of necrosis [48]. 
 Several  studies  investigated  the  relationship 
between p53 and other biological markers. Ringberg 
et al reported p53 expression to be positively corre-
lated  with  expression  of  ER,  PR,  HER2,  and  Bcl-2; 
however, Lebeau et al did not find p53 to be associ-
ated with either ER or PR [12, 16]. Lebeau et al also 
noted a correlation between p53 expression and lack 
of expression of cyclin D1 [12]. 
 We found ten studies (1,355 total patients) that 
looked at the relationship between p53 expression and 
local recurrence; only three of these studies showed 
an association. Ringberg et al used principal compo-
nents analysis to evaluate a cell biological index that 
included  ER  and  PR  negativity,  overexpression  of 
HER2,  low  Bcl-2  expression,  accumulation  of  p53, 
nondiploidy,  and  high  Ki-67  expression.  P53  when 
combined  with  these  biological  markers  was  a  pre-
dictor  of  local-regional  recurrence  [16].  The  specific 
rates  of  local  recurrence  associated  with  particular 
marker  phenotypes  were  not  discernible  from  the 
published report; however, the overall rate of recur-
rence  was  25.6%  among  121  patients  treated  with 
breast-conserving  surgery  without  radiotherapy. 
Hieken  et  al  reported  that  DCIS  that  recurred  was 
more likely than DCIS that did not recur to exhibit 
strong  p53  expression  (63%  vs.  24%,  Table  9)  [48]. 
Similarly, de Roos et al reported p53 expression to be 
an independent predictor of local recurrence (HR: 3.0, 
95% CI: 1.1-8.2, P=0.036, Table 9) [43]. 
Bcl-2 
Bcl-2 is one of the apoptosis regulator proteins. A 
deregulation in apoptosis due to imbalances in Bcl-2 
expression has been associated with the pathogenesis 
of breast cancer [49]. Bcl-2 has been shown to be an 
independent  prognostic  biomarker  in  early-stage 
breast cancer and nasopharyngeal carcinoma [50, 51]. 
Among the six studies in our review that examined 
Bcl-2  expression  rate  in  DCIS,  the  mean  expression 
rate of Bcl-2 in DCIS among six reported studies was 
55.4%  (range:  48–58.8%,  Table  4).  Warnberg  et  al 
found  a  higher  expression  of  Bcl-2  in 
well-differentiated  lesions  than  in  poorly  differenti-
ated  lesions  [36].  Several  investigators  studied  the 
relationship  between  Bcl-2  and  other  biological 
markers.  Ringberg  et  al  and  Provenzano  et  al  ob-
served a positive association between Bcl-2 expression 
and expression of ER and PR [16, 22]. Jirström et al 
also  observed  a  significant  negative  association  be-
tween Bcl-2 expression and overexpression of HER2 
[42]. 
 We identified three studies (433 total patients) 
that  investigated  the  association  between  Bcl-2  ex-
pression and risk of local-regional recurrence in DCIS. 
Cornfield et al found that Bcl-2 expression was not an 
independent predictor of local recurrence [46]. How-
ever, Provenzano et al found that DCIS that recurred 
was more likely than DCIS that did not recur to be 
Bcl-2  negative  (66%  vs.  26%,  respectively,  Table  9) 
[22]. 
Bax 
Bax is another protein that plays a role in pro-
moting apoptosis [52]. In gastric carcinoma, colorec-
tal,  and  pancreatic  cancer,  negative  Bax  expression 
has  been  shown  to  be  a  prognostic  predictor  [53]. 
According to Okumura et al, the rate of expression of 
Bax in DCIS was 71.2% (Table 4) [52]. Bax is one of the 
less  studied  proteins  in  DCIS;  we  were  unable  to 
identify studies that investigated the significance of 
Bax expression in terms of local recurrence of DCIS. Journal of Cancer 2011, 2 
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Survivin 
Survivin is another important protein in the cell 
cycle, responsible for cell cycle regulation and inhibi-
tion of apoptosis [52]. Okumura reported an expres-
sion rate of survivin in DCIS of 55.8% (Table 4) [52]. 
Barnes et al reported the expression of survivin ac-
cording  to  different  staining:  nuclear  staining,  10%; 
cytoplasmic staining, 29%; and cytoplasmic and nu-
clear staining, 29% [54]. Barnes et al reported no sig-
nificant  correlations  between  survivin  and  clinico-
pathological factors. We identified one study that in-
vestigated  the  recurrence  risk  associated  with  sur-
vivin [54]. In this study, patients with recurrence were 
more  likely  than  those  without  recurrence  to  have 
co-expression  of  COX-2  and  cytoplasmic  survivin 
(70% vs. 41%, Table 9) [54]. 
C-myc 
C-myc is a proto-oncogene that is known to play 
a role in proliferation, malignant transformation, and 
apoptosis. Although c-myc has been associated with 
poor prognosis in invasive breast cancer, few studies 
have evaluated c-myc expression levels in DCIS [55]. 
Altintas  et  al  reported  that  the  expression  rate  of 
c-myc in DCIS was 60% (Table 4)  [15]. In the same 
study, Altintas et al found that c-myc was not a pre-
dictor of local recurrence of DCIS (Table 9). 
Retinoblastoma 
Retinoblastoma (Rb) is a tumor suppressor pro-
tein  that  plays  an  important  role  in  regulating  cell 
growth. Okumura et al reported that the expression 
rate of Rb in DCIS was 68.6%. In the same study, the 
investigators found no significant difference in rates 
of Rb expression between pure DCIS and DCIS with 
microinvasion  [52].  Few  studies  have  evaluated  Rb 
expression levels in DCIS, and no studies investigat-
ing the relationship between Rb expression rate and 
local recurrence of DCIS met our selection criteria. 
Angiogenesis-Related Proteins 
Vascular endothelial growth factor 
Vascular  endothelial  growth  factor  (VEGF)  is 
one of the most potent angiogenic factors. It acts as a 
mitogen for endothelial cells and also increases vas-
cular  permeability  [48].  Our  review  included  two 
studies that investigated the expression rate of VEGF 
in DCIS. The mean value was 89.9% (rates in the two 
studies were 86.0% and 93.8%, Table 5). No studies in 
our comprehensive search found VEGF to be corre-
lated with clinicopathological parameters. One study 
investigated the relationship between VEGF and other 
biological  markers.  The  investigators  found  VEGF 
expression to be significantly associated with COX-2 
expression [20]. Only one study, by Hieken et al, in-
vestigated the relationship between VEGF expression 
and  local  recurrence  of  DCIS,  and  the  investigators 
found that VEGF was not an independent predictor of 
recurrence.  In  that  study,  DCIS  that  recurred  was 
more likely than DCIS that did not recur to express 
VEGF, but this difference did not reach statistical sig-
nificance (Table 9) [48]. 
Heparanase-1 
Heparanase-1  (HPR-1),  an  endo-β-D- 
glucuronidase, is responsible for cleaving the glyco-
sidic  side  chains  of  heparin  sulfate  proteoglycans. 
HPR-1 has not been extensively investigated in DCIS, 
even though an association has been found between 
HPR-1 and invasive cancer [56]. Maxhimer et al re-
ported that the expression rate of HPR-1 in DCIS was 
33.3%. The expression rate of HPR-1 was significantly 
higher  in  comedo  DCIS  than  in  noncomedo  DCIS 
(75%  vs.  14%).  The  investigators  found  that  tissues 
from normal breast did not express HPR-1 and that 
the  rate  of  expression  of  HPR-1  in  DCIS  with  mi-
croinvasion was 83% [56]. In our comprehensive re-
view,  we  did  not  identify  any  studies  on  the  rela-
tionship between expression of HPR-1 and recurrence 
of DCIS. 
Epidermal Growth Factor Receptor Family 
HER2 
Besides the steroid receptors, ER and PR, HER2 
is  one  of  the  most  extensively  studied  biological 
markers in DCIS. Studies have found HER2 to be of 
prognostic significance in invasive cancer; however, 
its importance in DCIS has yet to be elucidated [57]. 
Among the 36 studies in our review that examined 
HER2 expression rate in DCIS, the mean expression 
rate was 40.1% (range: 9–67%, Table 6). HER2 testing 
in majority of the studies was different. Some studies 
assessed  HER2  expression  based  on  membrane 
staining, whereas, other more recent studies assessed 
HER2 expression from the results of FISH amplifica-
tion. This complete information is included in Table 6. 
Expression rates of human epidermal growth factor receptor 
(HER)  family  in  DCIS  in  ―definition  of  positivity.‖ 
Most  of  the  studies  in  our  review  that  investigated 
HER2 expression rates by subtype found that HER2 
expression to be more common in the comedo sub-
type than in other subtypes of DCIS [7, 9, 17]. 
 Several  studies  investigated  the  relationship 
between HER2 and other biological markers. A few 
studies showed HER2 to be inversely correlated with 
ER  and  PR  expression  [9,  12,  17,  57].  One  study 
showed  HER2  to  be  positively  associated  with  p53 
expression [16]. A few studies showed HER2 overex-Journal of Cancer 2011, 2 
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pression  to  be  negatively  associated  with  Bcl-2  ex-
pression [16, 22]. The majority of the studies in our 
comprehensive review showed HER2 overexpression 
to be positively and significantly correlated with high 
nuclear grade [9, 10, 12, 17, 18, 22, 36, 57, 58]. How-
ever, one study did not show a significant association 
between  HER2  overexpression  and  grade  [20].  One 
study  showed  HER2  overexpression  to  be  signifi-
cantly correlated with proliferative activity [12]. In the 
same  study,  HER2  overexpression  was  significantly 
associated with p21 status [12]. 
 We  identified  15  (2,365  total  patients)  studies 
that  evaluated  the  relationship  between  HER2  ex-
pression and local recurrence in DCIS. Eleven of these 
studies  revealed  no  significant  correlation  between 
HER2  and  disease  recurrence.  As  mentioned  previ-
ously, Ringberg et al evaluated a cell biological index 
that included ER and PR negativity, overexpression of 
HER2,  low  Bcl-2  expression,  accumulation  of  p53, 
nondiploidy,  and  high  Ki-67  expression;  this  study 
showed  that  the  index  was  significantly  associated 
with disease recurrence  [16]. Provenzano et al, in a 
nested case-control study, found HER2 positivity to 
be individually associated with disease recurrence. In 
that study, DCIS that subsequently recurred was more 
likely than DCIS that did not recur to be HER2 posi-
tive (41% vs. 12%, Table 9). Kepple et al reported that 
HER2 positivity was an independent predictor of lo-
cal-regional  recurrence  and  that  HER2  positivity  in 
association with ER positivity was also a predictor of 
local-regional  recurrence.  However,  it  is  difficult  to 
interpret  the  effect  of  HER2  expression  on  local  re-
currence in this study because there were only 37 pa-
tients  who  underwent  breast-conserving  therapy 
(with or without radiotherapy), and only four patients 
had a recurrence [59]. Kerlikowske et al by multivari-
ate analysis did not find HER2 to be an independent 
predictor of disease recurrence, but they did find in 
the  univariate  analysis  that  HER2  individually  and 
the  phenotype  HER2+ER-Ki-67+  phenotype  were 
associated with DCIS recurrence. DCIS that recurred 
was more likely to exhibit the ER-HER2+ phenotype 
than was DCIS that did not recur (19% vs. 6.4%, re-
spectively, Table 9). In the multivariate analysis, the 
HER2+ ER-Ki-67+ phenotype was a strong predictor 
of  subsequent  DCIS  recurrence  (OR:  5.8;  95%  CI: 
2.4-14, Table 9). [24]. Zhou et al evaluated HER2 to-
gether with ER and PR and found that basal-like DCIS 
(negative for ER, PR, and HER2) was more likely to 
recur than was non-basal-like DCIS (HR: 1.7 vs. 1.8, 
Table 9). However, this difference did not reach sta-
tistical significance [25]. Holmes et al reported HER2 
overexpression to be an independent predictor of re-
currence. All the patients (n=141) in this study were 
treated  with  lumpectomy  alone,  and  60  (42.6%)  re-
currences were reported at a median follow-up of 10.2 
years.  In  the  univariate  analysis,  HER2  overexpres-
sion  was  significantly  related  to  time  to  recurrence 
(Table 9). In the multivariate analysis, HER2 positivity 
(3+) was a strong predictor of recurrence (HR: 1.82, 
95% CI: 1.03-3.22, P=0.041, Table 9). The overall re-
currence rate in this study, 42.6%, is considered to be 
high and may reflect the fact that the study covered a 
long time period, with some patients treated as early 
as 1983 [58]. 
HER1, HER3, and HER4 
Few studies have been conducted to investigate 
the rates of expression of HER1, HER3, and HER4 in 
DCIS  and  the  relationship  between  expression  of 
these markers and risk of local recurrence. The mean 
HER1  expression  rate  in  DCIS  in  the  three  studies 
included in our review was 23.8% (rates in the indi-
vidual studies were 13%, 22%, and 36.4%, Table 6). 
The mean HER3 expression rate in DCIS in the two 
studies included in our review was 59% (rates in the 
individual studies  were 56% and 62%, Table 6). Fi-
nally, the mean HER4 expression rate in DCIS in the 
two studies that we reviewed was 46% (rates in the 
individual studies were 37% and 55%, Table 6). No 
significant  correlations  were  observed  between  ex-
pression  of  these  three  biological  markers  and 
high-grade vs. low-grade DCIS [15]. Studies also in-
vestigated the relationship of HER1, HER2, and HER3 
to other markers. One study showed no correlation 
between these three biological markers and Ki-67 [15]. 
In the same study, overexpression of c-myc was sig-
nificantly  associated  with  HER3  and  HER4  overex-
pression;  however,  no  correlation  as  observed  be-
tween c-myc overexpression and HER1. 
 In our comprehensive search, we identified two 
studies that investigated the recurrence risk associat-
ed with the expression of HER1, HER3, and HER4. 
Altintas et al found that none of these three markers 
was  associated  with  disease  recurrence  either  indi-
vidually or in combination with other markers [15]. 
Barnes et al reported similar findings for HER1 and 
HER3; however, they observed that HER4 negativity 
was  an  independent  predictor  of  recurrence.  DCIS 
that did not recur was more likely than DCIS that did 
recur to overexpress HER4 (63.3% vs. 35.9%, respec-
tively, Table 9). Both of these studies also investigated 
patterns  of  co-expression  of  HER1-4  with  other 
markers. Barnes et al found that DCIS lesions with the 
combination  of  HER2  and  HER4  expression  were 
more  likely  to  express  ER  than  were  tumors  with 
HER2 expression without HER4 expression (73.2% vs. 
52.5%)  [35].  Altintas  et  al  found  that  DCIS  lesions Journal of Cancer 2011, 2 
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negative for both HER2 and HER4 were more likely to 
be high-grade lesions in cases (with a recurrence) than 
in controls (without a recurrence) (90% vs. 57.4%). In 
the multivariate analysis, expressions of HER1-4 were 
not independent predictors of local recurrence. In this 
study,  size,  margin  status,  grade/necrosis,  and  age 
were the only independent risk factors for local re-
currence [15]. 
Extracellular matrix-related proteins 
CD10 
CD10  is  a  zinc-dependent  membrane  metallo-
proteinase. This surface biomarker is also known as 
common acute lymphoblastic leukemia antigen [60]. 
The mean expression rate of CD10 in DCIS in the two 
studies included in our review was 22.9% (rates in the 
individual  studies  were  18.8%  and  27%,  Table  7). 
CD10 expression was found primarily in the myoep-
ithelial cells [60, 61]. In a cohort study, Toussaint et al 
evaluated normal breast tissue and samples of DCIS 
and observed expression of CD10 to be lower in DCIS 
samples than in normal breast tissue [60]. In another 
cohort study, Witkiewicz et al found a significant as-
sociation  between  the  expression  of  CD10  and 
younger patient age. This was the only study to in-
vestigate  the  relationship  between  CD10  and  other 
biological markers, and the investigators only found 
CD10 to be correlated with the glycoprotein secreted 
protein acidic and rich in cysteine (SPARC)  [61]. In 
our comprehensive search, we identified two studies 
that investigated the relationship between CD10 ex-
pression and risk of recurrence in DCIS. Toussaint et 
al found low (as opposed to high) CD10 mRNA level 
in DCIS samples to  be significantly associated with 
risk  of  recurrence  (HR:  2.39;  95%  CI:  1.52-3.76, 
P=0.001, Table 9). Of the 154 patients in this study, 20 
had  had  a  recurrence  (13%)  at  a  median  follow-up 
time of 6 years [60]. Interestingly, the opposite rela-
tionship  between  CD10  and  recurrence  risk  was 
found  by  Witkiewicz  et  al.  In  their  study,  strong 
stromal CD10 expression was significantly associated 
with disease recurrence (OR: 10.2, 95% CI: 2.7, 37.7, 
Table 9). This study included 97 patients, and 21 (re-
currence rate of 21.6%) had had a recurrence at a me-
dian follow-up time of 9.2 years [61]. 
Secreted Protein Acidic and Rich in Cysteine 
SPARC,  a  32-kDa  glycoprotein,  plays  an  im-
portant role in cell matrix interactions and cell cycle 
progression  [61]. We identified only one study that 
investigated  the  rate  of  SPARC  expression  in  DCIS 
and the relationship between SPARC expression and 
recurrence  in  DCIS.  Witkiewicz  et  al  reported  a 
SPARC expression rate of 24.7% (Table 7). These in-
vestigators found SPARC to be an independent pre-
dictor  of  recurrence:  patients  with  recurrence  were 
more likely than patients without recurrence to have 
strong stromal SPARC expression (OR: 3.9, 95% CI: 
1.1, 14.3) [61]. 
Cyclooxygenase-2 
COX-2  overexpression  has  been  shown  to  be 
upregulated in neoplastic and preneoplastic lesions in 
the  breast  [21].  COX-2  is  well  known  to  be  the 
rate-limiting  enzyme  in  prostaglandin  synthesis. 
Among the 10 studies in our review that examined 
COX-2 expression rate in DCIS, the mean COX-2 ex-
pression rate was 62.4% (range: 44.4–87.8%, Table 8). 
Gauthier et al found COX-2 expression to be associ-
ated  with  phospho-p38  staining.  P38,  a 
stress-activated kinase, is one of the few markers that 
has not been investigated in much depth in DCIS [62]. 
In this cohort of 30 DCIS cases that were available for 
immunostaining,  61%  of  the  cases  overexpressed 
COX-2; 83% and 87% of the cases, respectively, ex-
pressed  nuclear  and  cytoplasmic  phospho-p38.  All 
cases in which there was strong COX-2 staining ex-
hibited  moderate  to  high  nuclear  staining  of  phos-
pho-p38. However, in cases with high nuclear stain-
ing of phospho-p38, the intensity of COX-2 staining 
varied from low to high [62]. In a few studies, COX-2 
was observed to be significantly correlated with high 
nuclear grade [19, 63, 64]. One study showed COX-2 
expression to be correlated with cytoplasmic survivin 
expression in DCIS [54]. Another study found COX-2 
expression  to  be  significantly  associated  with  high 
Ki-67 expression, ER negativity, and HER2 positivity 
[19].  However,  another  study  did  not  find  COX-2 
overexpression  to  be  significantly  associated  with 
HER2 overexpression [21]. 
 We identified four studies that investigated the 
relationship  between  COX-2  expression  and  risk  of 
local-regional recurrence in DCIS. Barnes et al found 
greater COX-2 expression in DCIS that recurred than 
in DCIS that did not recur. Multivariate analysis re-
vealed COX-2 expression to be an independent pre-
dictor  of  recurrence  in  DCIS.  In  addition, 
co-expression of COX-2 and cytoplasmic survivin was 
found in 70% of the recurrent cases, whereas none of 
the  cases  lacking  expression  of  both  of  those  bi-
omarkers recurred within 5 years [54]. Kulkarni et al 
found  that  COX-2  expression  was  an  independent 
predictor  of  recurrence  in  both  the  univariate  and 
multivariate analyses. In addition, DCIS that recurred 
was more likely than DCIS that did not recur to ex-
press COX-2 (67% vs. 29%, respectively, Table 9) [21]. 
Gauthier et al found that high COX-2 expression in 
combination with high p16 expression and high Ki-67 Journal of Cancer 2011, 2 
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expression was a risk factor for recurrence [45]. In a 
follow-up study, Kerlikowske et al did not find COX-2 
to be an independent predictor or individually asso-
ciated with recurrence; however, COX-2 in combina-
tion  with  other  phenotypes  was  a  strong  predictor 
and  associated  with  recurrence.  In  the  univariate 
analysis,  cases  with  subsequent  invasive  recurrence 
were  more  likely  to  express  COX-2,  p16,  and  Ki-67 
than were cases that did not recur (23% vs. 8.5%, re-
spectively, Table 9) [24]. Cases with DCIS recurrence 
were  more  likely  than  cases  without  recurrence  to 
have the phenotype COX-2-Ki-67+p16+ (19% vs. 2.6%, 
Table 9). In the multivariate analysis, the p16, COX-2, 
and  Ki-67  triple-positive  phenotype  was  a  strong 
predictor of subsequent invasive recurrence (HR: 2.2; 
95%  CI:  1.1-4.5;  Table  9);  whereas  the 
p16+COX-2-Ki-67+ phenotype was a strong predictor 
of  subsequent  DCIS  recurrence  (HR:  3.7;  95%  CI: 
1.7-7.9;  Table  9).  [24].  The  study  by  Bundred  et  al 
discussed  earlier  in  this  article  revealed  that  use  of 
celecoxib,  a  COX-2  inhibitor,  for  2  weeks  prior  to 
surgery had no demonstrable effect on proliferation 
or apoptosis in DCIS [30]. These authors concluded 
that the use of COX-2 inhibitors would be unlikely to 
have a therapeutic value in DCIS [30]. 
Summary 
It  was  difficult  to  elucidate  the  prognostic  im-
portance of the biomarkers investigated in this com-
prehensive  review  because  of  heterogeneous  treat-
ment  approaches  and  often  conflicting  results.  Alt-
hough  the  studies  in  this  review  provide  valuable 
information on the diagnostic and prognostic signifi-
cance of the studied markers, another factor that lim-
its our ability to draw conclusions on the basis of the 
information in this review is the fact that many of the 
studies  reviewed  included  only  small  numbers  of 
patients.  Other  studies  included  groups  of  patients 
treated with different therapies, and in some studies 
the  treatment  was  inconsistent.  In  addition,  several 
studies included patients who had received endocrine 
therapy or radiotherapy, while other studies did not. 
This heterogeneous treatment makes it hard to assess 
clinical outcome. In conclusion, novel and key breast 
cancer biological markers need to be studied prospec-
tively in large cohorts of patient to differentiate indo-
lent  from  aggressive  DCIS  and  tailor  the  need  and 
extent of therapies. 
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Tables 
Table 1. Classification scheme of biological markers evaluated in the comprehensive review 
Steroid receptors  Estrogen receptor, progesterone receptor, and androgen receptor 
Proliferation marker  Ki-67   
Cell cycle regulation and apoptotic 
markers 
cyclin D1, cyclin A, cyclin E, p16, p21, p27, p53, Bcl-2, Bax, Survivin, c-myc, and retinoblastoma 
Angiogenesis related proteins  Vascular endothelial growth factor and heparanase-1 
Epidermal growth factor receptor family  HER1, HER2, HER3, and HER4 
Extracellular matrix related proteins  CD10 
Secreted protein acidic and rich in cysteine 
Other biological marker  COX-2 
 
 
Table 2. Expression rates of steroid receptors in DCIS 
Biomarker  First author and 
reference 
Year  No.  of  sam-
ples 
Expression 
rate, % 
Definition of positivity  
Estrogen receptor (ER) 
  Albonico [7]  1998  62  28.8–92.6  Nuclear staining in at least 10% of tumor cells.  
28.8 (comedo DCIS) 
78.9 (noncomedo DCIS) 
92.6 (cribriform DCIS) 
  Claus [9]  2001  219  60  No cut-off value was mentioned in the paper. 
  Bijker [10]  2001  116  62.9  Any ER expression. 
  Ringberg [16]  2001  187  60  Nuclear staining in more than 10% of tumor cells. 
  Wärnberg [36]  2001  194  68  Nuclear staining in at least 10% of tumor cells. 
  Oh [41]  2001  49  65.3  Nuclear staining in more than 5% of tumor cells. 
  Lebrecht [11]  2002  120  71.7  Moderate or strong nuclear staining in tumor cells. Journal of Cancer 2011, 2 
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  DiGiovanna [17]  2002  219  60  Nuclear staining in more than 10% of tumor cells. 
  Provenzano [22]  2003  95  49  Nuclear staining in at least 10% of tumor cells. 
  Lebeau [12]  2003  45  55  Nuclear staining in at least 10% of tumor cells. 
  Roka [23]  2004  190  57.9  Nuclear staining in at least 10% of tumor cells. 
  Boland [19]  2004  187  59.7  Nuclear staining in at least 5% of tumor cells. 
  Barnes [35]  2005  129  66.4  Nuclear staining in at least 5% of tumor cells. 
  Perrone [20]  2005  49  75.5  Nuclear staining in more than 10% of tumor cells. 
  Collins [13]  2005  148  77  Nuclear staining in at least 10% of tumor cells. 
  Gauthier [62]  2005  30  78.9  No cut-off value was mentioned in the paper. 
  Bryan [65]  2006  66  56  Nuclear staining in at least 10% of tumor cells. All cases were 
high-nuclear-grade DCIS. 
  Kepple [59]  2006  94  74  No cut-off value was mentioned in the paper 
  Wilson [37]  2006  129  65.1  Nuclear staining in at least 5% of tumor cells. 
  Barnes [54]  2006  161  63.6  Nuclear staining in at least 5% of tumor cells. 
  Millar [31]  2007  60  58.3  Nuclear staining in more than 10% of tumor cells. 
  Livasy [66]  2007  245  70  Allred score above 2. 
  Meijnen [14]  2008  163  68  Any ER expression. 
  Hanley [8]  2008  90  30 
(high-grade 
DCIS); 
96 
(non-high-gr
ade DCIS) 
Nuclear staining in at least 10% of tumor cells. 
  Tamimi [67]  2008  272  74  Nuclear staining in more than 10% of tumor cells. 
  Okumura [52]  2008  52  73.1  Nuclear staining in more than 10% of tumor cells. 
  Kulkarni [21]  2008  69  77.8  Nuclear staining in at least 10% of tumor cells. 
  Roses [68]  2009  84  76.2  Allred score less than or equal to 3. 
  Suzuki [69]  2009  58  60  Nuclear staining in at least 1% of tumor cells.  
  Altintas [15]  2009  159  72  Nuclear staining in at least10% of tumor cells. 
  Yu K [70]  2010  271  67.3  Results of immunohistochemical assays were evaluated using a 
proportion score and an intensity score. Tumors that scored over 1 
were scored as positive. 
  Kuerer [18]  2010  69  81  No cut-off value was mentioned in the paper. 
  Kerlikowske [24]  2010  329  77.9  Nuclear staining in at least 10% of tumor cells. 
  Behling [71]  2010  65  78  No cut-off value was mentioned in the paper. 
  Witkiewicz [61]  2010  97  96.6  Status obtained from the pathology reports. 
  Holmes [58]  2011  141  80.9  Nuclear staining was assessed in tumors and assigned a score. 
Tumors with staining in 0-9% of cells were given a score of 3, 
tumors with staining in 10-79% of cells were given a score of 2, 
and tumors with staining in 80% or more of cells were given a 
score of 1. Scores 1 and 2 were considered to be positive. 
Progesterone receptor (PR) 
  Albonico [7]  1998  62  28.2–89.1  Nuclear staining in at least 10% of tumor cells.  
28.2 (comedo DCIS) 
75.3 (noncomedo DCIS) 
89.1 (cribriform DCIS) 
  Claus [9]  2001  219  62  No cut-off value was mentioned in the paper. 
  Bijker [10]  2001  116  47.1  Any PR expression. 
  Ringberg [16]  2001  187  43  Nuclear staining in more than 10% of tumor cells. 
  Wärnberg [36]  2001  194  43  Nuclear staining in at least 10% of tumor cells. 
  DiGiovanna [17]  2002  219  62  Nuclear staining in more than 10% of tumor cells. 
  Provenzano [22]  2003  95  48  Nuclear staining in at least 10% of tumor cells. 
  Lebeau [12]  2003  45  50  Nuclear staining in at least 10% of tumor cells. 
  Roka [23]  2004  190  41  Nuclear staining in at least 10% of tumor cells. 
  Perrone [20]  2005  49  65.3  Nuclear staining in more than 10% of tumor cells. 
  Gauthier [62]  2005  30  70.8  No cut-off value was mentioned in the paper. 
  Bryan [65]  2006  66  40  Nuclear staining in at least 10% of tumor cells. All cases were 
high-nuclear-grade DCIS. 
  Kepple [59]  2006  94  56  No cut-off value was mentioned in the paper. Journal of Cancer 2011, 2 
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  Millar [31]  2007  60  56.1  Nuclear staining in more than 10% of tumor cells. 
  Meijnen [14]  2008  163  46  Any PR expression. 
  Hanley [8]  2008  90  23 
(high-grade 
DCIS); 
81 
(non-high-gr
ade DCIS) 
Nuclear staining in at least 10% of tumor cells. 
  Tamimi [67]  2008  272  59.9  Nuclear staining in more than 10% of tumor cells. 
  Okumura [52]  2008  52  71.2  Nuclear staining in more than 10% of tumor cells. 
  Kulkarni [21]  2008  69  75.9  Nuclear staining in more than 10% of tumor cells. 
  Roses [68]  2009  84  68.3  Allred score less than or equal to 3. 
  Suzuki [69]  2009  58  55  Nuclear staining in at least 1% of tumor cells.  
  Altintas [15]  2009  159  65  Nuclear staining in at least 10% of tumor cells. 
  Yu K [70]  2010  271  52.7  Results of immunohistochemical assays were evaluated using a 
proportion score and an intensity score. Tumors that scored over 1 
were scored as positive. 
  Bundred [30]  2010  90  72  Nuclear staining in more than 5% of tumor cells. All cases were 
ER-positive DCIS. 
  Kerlikowske [24]  2010  329  74.5  Nuclear staining in at least 10% of tumor cells. 
  Behling [71]  2010  65  71.2  No cut-off value was mentioned in the paper. 
  Witkiewicz [61]  2010  97  83.3  Status obtained from pathology reports. 
  Holmes [58]  2011  141  70.9  Nuclear staining was assessed in tumors and assigned a score. 
Tumors with staining in 0-9% of cells were given a score of 3, 
tumors with staining in 10-79% of cells were given a score of 2, 
and tumors with staining in 80% or more of cells were given a 
score of 1. Scores 1 and 2 were considered to be positive. 
Androgen receptor (AR) 
  Provenzano [22]  2003  95  81  Nuclear staining in at least 10% of tumor cells. 
  Meijnen [14]  2008  163  37  Strong nuclear staining in more than 10% of tumor cells. 
  Hanley [8]  2008  90  89 
(non-high-gr
ade DCIS); 
93 
(high-grade 
DCIS) 
Nuclear staining in at least 10% of tumor cells. 
  Yu Q. [33]  2010  34  79.4  Allred score of 2. 
 
 
Table 3. Expression rates of proliferation marker Ki-67 in DCIS 
Biomarker   First  author  and 
reference 
Year  No.  of 
samples 
Expression 
rate, % 
Comments 
Ki-67 
  Albonico [7]  1998  62  3.4–65.4  Tumors with nuclear staining in more than 13% of cells 
were scored as positive.  
65.4 (comedo DCIS) 
7.5 (noncomedo DCIS) 
3.4 (cribriform DCIS) 
  Ringberg [16]  2001  187  42  42% of cases exhibited staining in more than 10% of the 
tumor cells. 
  Menter [72]  2001  200  0.99–2.59  Ki-67 labeling index was determined by computerized 
image analysis. The range of Ki-67 labeling index in DCIS 
nuclear grades I-III was 0.99–2.59. 
  Wärnberg [36]  2001  194  19  19% of cases exhibited staining in at least 10% of the tumor 
cells. 
  Lebeau [12]  2003  45  45.5  45.5% of cases exhibited staining in more than 10% of the 
tumor cells. 
  Boland [19]  2004  187  49.2  The percentage of positively stained nuclei (at least 1,000 
cells were counted for each case) was determined using a 
grid graticule and cell counter at X400 magnification. 50.8% 
of cases exhibited staining in at least 10% of tumor cells. 
  Barnes [35]  2005  129  10.9 (nonre-
current 
The percentage of positively stained nuclei (at least 1,000 
cells were counted for each case) was determined using a Journal of Cancer 2011, 2 
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DCIS); 
15.5 (recur-
rent DCIS) 
grid graticule and cell counter at X400 magnification. The 
median percentage of cells with Ki-67 expression was 
10.9–15.5%  
  Barnes [54]  2006  161  8.7–14.4  The percentage of positively stained nuclei (at least 1,000 
cells were counted for each case) was determined using a 
grid graticule and cell counter at X400 magnification. The 
median percentage of cells with Ki-67 expression was 
8.7–14.4%. 
  Wilson [37]  2006  129  50.4  The percentage of positively stained nuclei (at least 1.000 
cells were counted for each case) was determined using a 
grid graticule and cell counter at X400 magnification. 50.4% 
of cases exhibited staining in at least 10% of tumor cells. 
  Gauthier [45]  2007  70  37.1  37.1% of cases exhibited staining in more than 10% of the 
tumor cells. 
  Livasy [66]  2007  245  36  36% of cases exhibited staining in more than 10% of the 
tumor cells. 
  Okumura [52]  2008  52  17.9  The percentage of cancer cells with positively stained nuclei 
was determined. The mean percentage Ki-67 staining was 
17.9 ± 1.5%. 
  Altintas [15]  2009  159  36  36% of cases exhibited staining in more than 10% of the 
tumor cells. 
  Kuerer [18]  2010  69  44.29 ± 3.42  No cut-off value was mentioned in the paper. The mean (± 
standard deviation) percentage of cells with Ki-67 staining 
was 44.29 ± 3.42%. Only patients with HER2-positive DCIS 
were included in the study. 
  Kerlikowske [24]  2010  329  47.5  47.5% of cases exhibited staining in more than 10% of the 
tumor cells, and thus 47.5% was set as the median value 
(positive cells divided by the number of positive plus neg-
ative cells) to divide cases with low and high proliferative 
activity. 
  Bundred [30]  2010  90  13.5–20.7  Ki-67 scores were calculated as the percentage of positively 
stained nuclei. The median percentages in each of the dif-
ferent treatment subgroups in this randomized trial were 
reported before patients were given aromatase inhibitor 
therapy. All patients had ER-positive DCIS. 
 
 
Table 4. Expression rates of cell cycle regulation and apoptotic markers in DCIS 
Biomarker   First  author  and 
reference 
Year  No.  of 
samples 
Expression 
rate, % 
Definition of positivity  
cyclin D1 
  Oh [41]  2001  49  59.2  Moderate or strong nuclear staining in more than 10% of 
tumor cells. 
  Lebeau [12]  2003  45  48.8  Nuclear staining in more than 10% of tumor cells. 
  Chasle [38]  2003  50  37  The percentage of marked nuclei was determined for 
300-400 nuclei in the most positive foci. The mean for cyclin 
D1 was reported to be 37%. 
  Millar [31]  2007  60  58  Nuclear staining in more than 5% of tumor cells. 
  Okumura [52]  2008  52  70.6  Nuclear staining in more than 10% of tumor cells. 
  Kulkarni [21]  2008  69  61.5  Nuclear staining in at least 10% of tumor cells. 
cyclin A 
  Millar [31]  2007  60  35  Nuclear staining in more than 10% of tumor cells. 
cyclin E 
  Jirström  [42]  2003  92  25  A mean value was used as a cut-off to divide expression of 
cyclin E. 
p16 
  Jirström  [42]  2003  92  37.5  A mean value was used as a cut-off to divide expression of 
p16. 
  Gauthier [45]  2007  70  28  Allred score of at least 2. 
  Kerlikowske [24]  2010  329  39.3  On a 3-point scale, a score of at least 2. 
p21 
  Oh [41]  2001  49  67.3  Moderate or strong nuclear staining in more than 10% of 
tumor cells. 
  Provenzano [22]  2003  95  34  On a 6-point scale, a score of 4-6 (moderate or strong stain-Journal of Cancer 2011, 2 
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ing). 
  Lebeau [12]  2003  45  42.2  Nuclear staining in more than 10% of tumor cells. 
  Chasle [38]  2003  50  76  The percentage of marked nuclei was determined for 
300-400 nuclei in the most positive foci.  
  Okumura [52]  2008  52  69.2  Nuclear staining in more than 10% of tumor cells. 
  Kulkarni [21]  2008  69  29.6  Nuclear staining in at least 10% of tumor cells. 
p27 
  Oh [41]  2001  49  46.9  Moderate or strong nuclear staining in more than 10% of 
tumor cells. 
  Jirström [42]  2003  92  68.5  Nuclear and cytoplasmic staining intensity were evaluated 
using a 3-point semiquantitative scoring scale (0=none, 
1=weak, 2=moderate, 3=strong). 
  Millar [31]  2007  60  55  Nuclear staining in more than 50% of tumor cells. 
p53 
  Albonico [7]  1998  62  7.0–37.3  Nuclear staining in more than 5% of tumor cells.  
37.3 (comedo DCIS) 
17.2 (noncomedo DCIS) 
7.0 (cribriform DCIS) 
  Bijker [10]  2001  116  20  On an 8-point scale, a score of at least 5. 
  Ringberg [16]  2001  187  26  Nuclear staining in more than 10% of tumor cells. 
  Hieken [48]  2001  103  27  Strong nuclear staining in more than 10% of tumor cells. 
  Wärnberg [36]  2001  194  40  Any p53 expression.  
  Oh [41]  2001  49  30.6  Nuclear staining in more than 5% of tumor cells. 
  Provenzano [22]  2003  95  60  On a 6-point scale, a score of 4-6 (moderate or strong stain-
ing). 
  Lebeau [12]  2003  45  25  Moderate or strong nuclear staining in more than 40% of 
tumor cells. 
  Chasle [38]  2003  50  88  The percentage of marked nuclei was determined for 
300-400 nuclei in the most positive foci. 
  Roka [23]  2004  190  57.2  Nuclear staining in at least 10% of tumor cells. 
  Perrone [20]  2005  49  26.5  Nuclear staining in more than 10% of tumor cells. 
  Kepple [59]  2006  94  50  No cut-off value was mentioned in the paper. 
  Livasy [66]  2007  245  31  Nuclear or nuclear and cytoplasmic staining in more than 
10% of tumor cells. 
  Meijnen [14]  2008  163  26  Nuclear staining in more than 25% of tumor cells. 
  Okumura [52]  2008  52  76.5  Nuclear staining in more than 10% of tumor cells. 
  Kulkarni [21]  2008  69  67.9  Nuclear staining in at least 10% of tumor cells. 
  Kerlikowske [24]  2010  329  11.3  Nuclear staining in at least 10% of tumor cells. 
Bcl-2 
  Albonico [7]  1998  62  35.7–100  Nuclear staining in more than 10% of tumor cells.  
35.7 (comedo DCIS) 
100 (noncomedo DCIS) 
100 (cribriform DCIS) 
  Ringberg [16]  2001  187  56  Cytoplasm staining in more than 10% of tumor cells. 
  Wärnberg [36]  2001  194  48  Nuclear staining in at least 10% of tumor cells. 
  Provenzano [22]  2003  95  50  On a 6-point scale, a score of 4-6 (moderate or strong stain-
ing). 
  Meijnen [14]  2008  163  64  Weak cytoplasmic staining in more than 10% of tumor cells. 
  Okumura [52]  2008  52  58.8  Nuclear staining in more than 5% of tumor cells. 
Bax 
  Okumura [52]  2008  52  71.2  Nuclear staining in more than 5% of tumor cells. 
Survivin 
  Barnes [54]  2006  161  10 (nuclear 
staining 
alone); 
29% (cyto-
plasmic 
staining 
alone); 
29% (cyto-
plasmic and 
nuclear 
staining) 
Survivin staining was scored for both cytoplasmic and 
nuclear staining. For cytoplasmic staining, a score of at least 
2 was considered positive; for nuclear staining, the propor-
tion of positive cells out of at least 1,000 was determined. Journal of Cancer 2011, 2 
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  Okumura [52]  2008  52  55.8  Nuclear staining in more than 5% of tumor cells. 
C-myc 
  Altintas [15]  2009  159  60  Score of at least 2.  
Rb 
  Okumura [52]  2008  52  68.6  Nuclear staining in more than 10% of tumor cells. 
 
 
Table 5. Expression rates of angiogenesis related proteins in DCIS 
Biomarker   First  author  and 
reference 
Year  No.  of 
samples 
Expression 
rate, % 
Definition of positivity 
Vascular endothelial growth factor (VEGF) 
  Hieken [48]  2001  103  86  Cytoplasmic and/or membrane staining in more than 10% 
of tumor cells. 
  Perrone [20]  2005  49  93.8  Staining (defined as appropriate brown staining in the 
tumor cell cytoplasm) in more than 10% of tumor cells.  
Heparanase-1 (HPR1) 
  Maxhimer [56]  2005  45  42.2  Nuclear staining in more than 20% of tumor cells. 
 
 
Table 6. Expression rates of human epidermal growth factor receptor (HER) family in DCIS 
Biomarker   First  author  and 
reference 
Year  No.  of 
samples 
Expression rate, 
% 
Definition of positivity 
Human epidermal growth factor receptor 1 (HER1) 
  Lebeau [12]  2003  45  36.4  Any distinctive membrane staining of intraductal tumor 
cells. 
  Bryan [65]  2006  66  22  Any cytoplasmic and/or membranous staining of tumor 
cells. 
  Altintas [15]  2009  159  13  Score of at least 2 
HER2/neu (HER2) 
  Albonico [7]  1998  62  1.0–72.8  Staining in more than 10% of tumor cells.  
72.8 (comedo DCIS) 
10.8 (noncomedo DCIS) 
1.0 (cribriform DCIS) 
  Claus [9]  2001  219  28  On a 4-point scale, any score other than 0. 
  Bijker [10]  2001  116  46.2  Any expression. 
  Ringberg [16]  2001  187  54  Membrane staining in more than 10% of tumor cells. 
  Wärnberg [36]  2001  194  55  Moderate or strong membrane staining in at least 30% of 
tumor cells or complete membrane staining in more than 
60% of tumor cells regardless of the intensity of the 
staining.  
  Latta [57]  2002  91  34.1  On an 8-point scale, an IHC score of at least 5. In addition, 
a HER2/CEP17 ratio of at least 2 was considered positive 
for HER2/neu gene amplification. 
  DiGiovanna [17]  2002  219  28  On a 4-point scale, any score other than 0. 
  Hoque [73]  2002  100  40  HER2 gene amplification was analyzed by FISH. A ratio 
of greater than 2.0 was considered indicative of HER2 
gene amplification. 
  Provenzano [22]  2003  95  32  Strong staining (equivalent to a score of 3+ with the 
DakoCytomation HercepTest).  
  Lebeau [12]  2003  45  46.7  On a 3-point scale, a score of greater than 2. Scoring was 
based on the positive staining of the cell membrane. 
  Roka [23]  2004  190  41.3  Nuclear staining in more than 30% of tumor cells. 
  Boland [19]  2004  187  54.5  On a 3-point scale, a score of at least 2.  
  Barnes [35]  2005  129  65  Score of at least 2.  
  Perrone [20]  2005  49  66.7  Complete membrane staining in more than 10% of tumor 
cells. 
  Collins [13]  2005  148  28  Strong membrane staining in more than 10% of tumor 
cells (equivalent to a score of 3+ with the DakoCytomation 
HercepTest). Journal of Cancer 2011, 2 
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  Bryan [65]  2006  66  67  Membrane staining in more than 10% of tumor cells 
(equivalent to a score of 3+ in the DakoCytomation Her-
cepTest). All cases were high-nuclear-grade DCIS. 
  Kepple [59]  2006  94  27  No cut-off value was mentioned in the paper. 
  Wilson [37]  2006  129  64.8  On a 3-point scale, a score of at least 2. 
  Barnes [54]  2006  161  64.7  Score of at least 2.  
  Livasy [66]  2007  245  25  3+ intensity with DAB chromogen and 2+ or 3+ intensity 
with the SG chromogen in more than 10% of tumor cells. 
  Meijnen [14]  2008  163  39  Strong membranous staining in more than 10% of tumor 
cells. 
  Hanley [8]  2008  90  9 
(non-high-grade 
DCIS); 
55 (high-grade 
DCIS) 
Membrane staining of 3+. 
  Tamimi [67]  2008  272  27.2  Moderate or strong membrane staining (2+ of higher on a 
3-point scale) in at least 10% of tumor cells.  
  Okumura [52]  2008  52  17.3  On a 3-point scale, a score of 3 (strong staining). 
  Kulkarni [21]  2008  69  60.4  On a 3-point scale, 3+ staining in more than 10% of tumor 
cells. 
  Roses [68]  2009  84  28.6  Membranous staining of 3+ in any tumor cell or mem-
branous staining of 2+ in more than 10% of tumor cells 
with fluorescence in situ hybridization evidence of HER2 
gene amplification. 
  Suzuki [69]  2009  58  9  On a 3-point scale, a score of 3 or positive for HER2 gene 
amplification when HER2/CEP17 greater than 2.2. 
  Altintas [15]  2009  159  40  Score of at least 2.  
  Yu K [70]  2010  271  33.7  Results of immunohistochemical assays were evaluated 
using a proportion score and an intensity score. HER2 
status was defined as positive for scores of 9-12. 
  Stackievicz [74]  2010  84  44  Moderate or strong membrane staining (2+ or higher on a 
3-point scale) in more than 10% of tumor cells. 
  Kuerer [18]  2010  69  35  On a 3-point scale, a 3+ score was considered to be posi-
tive by IHC or positive for HER2 gene amplification when 
HER2/CEP17 ratio greater than 2.0 by FISH.  
  Bundred [30]  2010  90  32  On a 3-point scale, a score of greater than 2. All cases were 
ER-positive DCIS. 
  Kerlikowske [24]  2010  329  18.2  Moderate or strong membrane staining (2+ or higher)in at 
least 10% of tumor cells. 
  Behling [71]  2010  65  50  No cut-off value was mentioned in the paper. 
  Witkiewicz [61]  2010  97  33.3  Status obtained from pathology reports. 
  Holmes [58]  2011  141  27.7  On a 3-point scale, a score of 3. 
HER3 
  Barnes [35]  2005  129  56  Score of at least 2.  
  Altintas [15]  2009  159  62  Score of at least 2. 
HER4 
  Barnes [35]  2005  129  55  Score of at least 2. 
  Altintas [15]  2009  159  37  Score of at least 2. 
FISH, fluorescence in situ hybridization; IHC, immunohistochemical. 
 
Table 7. Expression rates of extracellular matrix-related proteins in DCIS 
Biomarker   First  author  and 
reference 
Year  No.  of 
samples 
Expression 
rate, % 
Definition of positivity 
CD10 
  Toussaint [60]  2010  154  27  CD10 scoring was based on expression and intensity values. 
A high score was determined to be equivalent to 6. 
  Witkiewicz [61]  2010  97  18.8  On a 3-point scale, a score of 2 (defined as strong staining of 
at least 30% of stromal cells). 
SPARC 
  Witkiewicz [61]  2010  97  24.7  On a 3-point scale, a score of 2 (defined as strong staining of 
at least 30% of stromal cells). Journal of Cancer 2011, 2 
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Table 8. Expression rate of COX-2 in DCIS 
Biomarker   First  author  and 
reference 
Year  No.  of 
samples 
Expression 
rate, % 
Definition of positivity 
  Tan [63]  2004  51  80  On a 9-point scale, 0 was considered to be nil; 1-3 was con-
sidered to be mild; 4-6 was considered to moderate; 7-9 was 
considered to be strong. Only unequivocal cytoplasmic 
staining was regarded as positive. 
  Boland [19]  2004  187  67  On a 3-point scale, a score of at least 2. Expression was 
based on the extent and intensity of epithelial cell staining. 
  Perrone [20]  2005  49  87.8  On a 12-point scale for immunoreactivity, an immuno-
histochemistry score of 9-12 was considered strong, 5-8 was 
considered moderate, 1-4 was considered weak, and 0 was 
considered negative. 
  Gauthier [62]  2005  30  60.7  No cut-off value was mentioned in the paper. 
  Barnes [54]  2006  161  72  Score of at least 2. 
  Gauthier [45]  2007  70  55.7  Allred score of at least 2. 
  Kulkarni [21]  2008  69  45.8  Cytoplasmic granular staining in more than 10% of tumor 
cells. 
  Bundred [30]  2010  90  58  A minimum of 500 cells was investigated across randomly 
selected areas of DCIS at a magnification of x 400 using a 
grid graticule and cell counter for each of the two sections. 
All cases were ER-positive DCIS. 
  de la Torre [64]  2010  52  53  On a 3-point scale, a score of at least 2. 
  Kerlikowske [24]  2010  329  44.4  On a 3-point scale, a score of at least 2. 
 
 
Table 9. Biomarker expression and ipsilateral recurrence risk following surgery for DCIS  
Biomarker  First author 
and refer-
ence 
Year  No. of pa-
tients 
Treatment groups  Median 
fol-
low-up 
time, 
months 
Endocrine 
therapy 
use 
Marker ex-
pression as-
sociated with 
increased risk 
of lo-
cal-regional 
recurrence 
Comments 
Steroid Receptors 
ER 
  Ringberg 
[16] 
2001  187  Lumpectomy with 
XRT—66; Lumpec-
tomy without 
XRT—121 
62  No  Yes (when 
combined 
with other 
biological 
markers) 
The investigators evaluated a cell 
biological index (CBI-7) that in-
cluded ER and PR negativity, 
overexpression of HER2, low Bcl-2 
expression, accumulation of p53, 
nondiploidy, and high Ki-67 ex-
pression. ER negativity combined 
with all those markers was a 
strong predictor of recurrence (RR: 
1.3; 95% CI: 1.0-1.6; P=0.051). 
  Provenzano 
[22] 
2003  95 (53 cases 
and 42 con-
trols) 
Lumpectomy 
without XRT—85; 
Lumpectomy with 
XRT—10 
101  Yes  Yes  Patients with local-regional recur-
rence were more likely than pa-
tients without recurrence to have 
ER-negative disease (62% vs. 35%; 
OR: 0.2; P=0.01). ER negativity was 
individually associated with re-
currence. 
  Roka [23]  2004  190  Lumpectomy 
without XRT—33; 
Lumpectomy with 
XRT—99; Mastec-
tomy with XRT—58 
61.6  Yes  Yes  The recurrence rate was higher for 
ER-negative DCIS than for 
ER-positive DCIS (12.2% vs. 3.7%; 
P<0.04). 
  Cornfield 
[46] 
2004  151  All patients were 
treated with lum-
pectomy without 
65  No  No  ER was not associated with disease 
recurrence in either univariate or 
multivariate analysis. Journal of Cancer 2011, 2 
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  Barnes [35]  2005  129  Lumpectomy—89; 
Mastectomy—40 
(8 patients received 
XRT) 
Not 
pro-
vided 
No  No  ER was not associated with disease 
recurrence in multivariate analy-
sis. 
  Kepple [59]  2006  94  Lumpectomy 
without XRT—17; 
Lumpectomy with 
XRT—20; Mastec-
tomy—57 
48 
months 
Yes  Unknown  Difficult to assess effect. Only 37 
patients underwent lumpectomy, 
and there were only 4 recurrences 
in that group. Some of those 37 
patients received radiotherapy and 
some did not. 
  Barnes [54]  2006  161  Lumpectomy—103; 
Mastectomy—47; 
Information una-
vailable for 11 pa-
tients. No infor-
mation available on 
XRT 
Not 
pro-
vided 
Unknown  No   ER was not associated with disease 
recurrence in multivariate analy-
sis. 
  Wilson [37]  2006   129  Patients underwent 
definitive surgery 
for DCIS, but no 
details were pro-
vided  
Not 
pro-
vided 
No  No  ER was not associated with disease 
recurrence in either univariate or 
multivariate analysis. 
  de Roos [43]  2007  87   Lumpectomy—39; 
Mastectomy—48 
(21 patients re-
ceived XRT) 
49.8  No  No  ER was not associated with disease 
recurrence in either univariate or 
multivariate analysis. 
  Millar [31]  2007  60  Lumpectomy with 
or without XRT—56 
(51 received XRT); 
Mastectomy with-
out XRT—4  
98  No  No  In the univariate analysis con-
ducted with clinicopathological 
parameters, ER was not associated 
with disease recurrence. 
  Kulkarni 
[21] 
2008  69  Lumpectomy 
without XRT—26; 
Lumpectomy with 
XRT—43 
Mean 
time to 
recur-
rence: 
38.5 
Yes  No  The investigators concluded that 
the biological marker, ER, is not an 
independent predictor of recur-
rence. 
  Altintas [15]  2009  159  Lumpectomy—112; 
Mastectomy—45 
Information una-
vailable for 2 pa-
tients. No infor-
mation available on 
XRT 
54  No  No  The investigators concluded that 
the biological marker, ER, is not an 
independent predictor of recur-
rence. 
  Kerlikow-
ske [24] 
2010  329 
(Controls 
with no re-
currence, 186; 
cases with 
invasive re-
currence, 72; 
cases with 
DCIS recur-
rence, 71) 
All patients were 
treated with lum-
pectomy alone 
98  No  Yes (when 
combined 
with other 
biomarkers) 
In the univariate analysis, patients 
with DCIS recurrence were more 
likely than those without recur-
rence to have ER-negative disease 
(31% vs. 20%). ER negativity was 
individually associated with DCIS 
recurrence. In addition, ER nega-
tivity combined with either HER2 
positivity or Ki-67 positivity was 
also associated with DCIS recur-
rence. In the multivariate analysis, 
the phenotype ER-HER2+Ki-67+ 
was a strong predictor of subse-
quent DCIS recurrence (HR: 5.8; 
95% CI: 2.4-14). 
  Zhou [25]  2010  392  Lumpectomy 
without XRT—158; 
Lumpectomy with 
XRT—140; Mastec-
tomy —94  
97.5  No  No  The investigators looked at ba-
sal-like tumors (tumors negative 
for ER, PR, and HER2). In the 
univariate and multivariate anal-
yses, basal-like DCIS was associ-
ated with a higher risk of invasive 
recurrence than non-basal-like 
DCIS. However, the difference 
was not statistically significant. 
  Witkiewicz 
[61] 
2010  97  All patients under-
went lumpectomy; 
no information was 
available about XRT 
110.8  No  No  The investigators did not find ER 
to be an independent predictor of 
recurrence. 
  Holmes [58]  2011  141  All patients under-
went lumpectomy 
alone 
125  No  No  In the univariate and multivariate 
analyses, ER was not a predictor of 
recurrence. Journal of Cancer 2011, 2 
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PR 
  Ringberg 
[16] 
2001  187  Lumpectomy with 
XRT—66; Lumpec-
tomy without 
XRT—121 
62  No  Yes (when 
combined 
with other 
biological 
markers) 
The investigators evaluated a cell 
biological index (CBI-7) that in-
cluded ER and PR negativity, 
overexpression of HER2, low Bcl-2 
expression, accumulation of p53, 
nondiploidy, and high Ki-67 ex-
pression. PR negativity combined 
with all those markers was a 
strong predictor of recurrence (RR: 
1.3; 95% CI: 1.0-1.6; P=0.051). 
  Provenzano 
[22] 
2003  95   Lumpectomy 
without XRT—85; 
Lumpectomy with 
XRT—10 
101  Yes  Yes  Patients with local-regional recur-
rence were more likely than those 
without recurrence to have 
PR-negative disease (63% vs. 34%; 
OR: 0.2; P=0.04). PR negativity was 
individually associated with re-
currence. 
  Roka [23]  2004  190  Lumpectomy 
without XRT—33; 
Lumpectomy with 
XRT—99; Mastec-
tomy with XRT—58 
61.6  Yes  No  PR-negative DCIS was associated 
with a higher rate of recurrence 
than PR-positive DCIS (9.1% vs. 
3.6%), but this difference did not 
reach statistical significance. 
  Cornfield 
[46] 
2004  151  All patients were 
treated with lum-
pectomy alone 
 
65  No  No  PR was not associated with disease 
recurrence in either univariate or 
multivariate analysis. 
  Kepple [59]  2006  94  Lumpectomy 
without XRT—17; 
Lumpectomy with 
XRT—20; Mastec-
tomy—57 
48 
months 
Yes  Unknown  Difficult to assess effect. Only 37 
patients underwent lumpectomy, 
and there were only 4 recurrences 
in that group. Some of those 37 
patients received radiotherapy and 
some did not. 
  de Roos [43]  2007  87  Lumpectomy—39; 
Mastectomy—48 
(21 patients re-
ceived XRT) 
49.8  No  No  PR was not associated with disease 
recurrence in either univariate or 
multivariate analysis. 
  Millar [31]  2007  60  Lumpectomy with 
or without XRT—56 
(51 received XRT); 
Mastectomy with-
out XRT—4 
98  No  No  In the univariate analysis con-
ducted with clinicopathological 
parameters, PR was not associated 
with disease recurrence. 
  Kulkarni 
[21] 
2008  69  Lumpectomy 
without XRT—26; 
Lumpectomy with 
XRT—43 
Mean 
time to 
recur-
rence: 
38.5 
Yes  No  The investigators concluded that 
the biological marker, PR, is not an 
independent predictor of recur-
rence. 
  Altintas [15]  2009  159  Lumpectomy—112; 
mastectomy—45 
Information una-
vailable for 2 pa-
tients. No infor-
mation available on 
XRT 
54  No  No  The investigators concluded that 
the biological marker, PR, is not an 
independent predictor of recur-
rence. 
  Zhou [25]  2010  392  Lumpectomy 
without XRT—158; 
Lumpectomy with 
XRT—140; Mastec-
tomy —94 
97.5  No  No  The investigators looked at ba-
sal-like tumors (tumors negative 
for ER, PR, and HER2). In the 
univariate and multivariate anal-
yses, basal-like DCIS was associ-
ated with a higher risk of local 
recurrence (HR: 1.7) than 
non-basal-like DCIS (HR: 1.8). 
However, the difference was not 
statistically significant. 
  Kerlikow-
ske [24] 
2010  329 
(Controls 
with no re-
currence, 186; 
cases with 
invasive re-
currence, 72; 
cases with 
DCIS recur-
rence, 71) 
All patients were 
treated with lum-
pectomy alone 
98  No  No  PR was not associated with inva-
sive or DCIS recurrence in either 
univariate or multivariate analysis. 
  Witkiewicz 
[61] 
2010  97  All patients under-
went lumpectomy 
(no information was 
110.8  No  No  The investigators did not find PR 
to be an independent predictor of 
recurrence. Journal of Cancer 2011, 2 
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available about 
XRT) 
  Holmes [58]  2011  141  All patients under-
went lumpectomy 
alone 
125  No  No  PR was not associated with disease 
recurrence in either univariate or 
multivariate analysis. 
AR 
  Provenzano 
[22]  
2003  95   Lumpectomy 
without XRT—85; 
Lumpectomy with 
XRT—10 
101  Yes  No  The investigators did not find AR 
to be associated with disease re-
currence. 
Proliferation marker Ki-67 
  Ringberg 
[16] 
2001  187  Lumpectomy with 
XRT—66; Lumpec-
tomy without 
XRT—121 
62  No  Yes (when 
combined 
with other 
biological 
markers) 
The investigators evaluated a cell 
biological index (CBI-7) that in-
cluded ER and PR negativity, 
overexpression of HER2, low Bcl-2 
expression, accumulation of p53, 
nondiploidy, and high Ki-67 ex-
pression. High Ki-67 expression 
combined with all those markers 
was a strong predictor of recur-
rence (RR: 1.3; 95% CI: 1.0-1.6; 
P=0.051). 
  Chasle [38]  2003  50  All patients under-
went lumpectomy 
followed by XRT 
Un-
known 
No  Yes (when 
combined 
with cyclin A) 
A global proliferation factor (GPF) 
was calculated that was a sum of 
Ki-67 and cyclin A. In both uni-
variate and multivariate analyses, 
GPF was an independent predictor 
of recurrence. 
  Cornfield 
[46] 
2004  151  All patients were 
treated with lum-
pectomy alone 
 
65  No  No  Ki-67 was not associated with 
disease recurrence in either uni-
variate or multivariate analysis. 
  Barnes [35]  2005  129  Lumpectomy—89; 
Mastectomy—40 
(8 patients received 
XRT) 
Not 
pro-
vided 
No  Yes  Patients with recurrence were 
more likely than patients without 
recurrence to have high prolifera-
tive activity (15.5% vs. 10.9%; 
P=0.005). In the multivariate anal-
ysis, Ki-67 was an independent 
predictor of recurrence (OR: 1.03, 
95% CI: 1.00-1.06; P=0.038) 
  Wilson [37]  2006   129  Patients underwent 
definitive surgery 
for DCIS, but no 
details were pro-
vided  
Not 
pro-
vided 
No  No  In the univariate analysis, patients 
with recurrence were more likely 
than patients without recurrence 
to have high proliferative activity 
compared to patients without a 
recurrence (71.4 vs. 42.2%, 
P=0.006). However, in the multi-
variate analysis, Ki-67 was not an 
independent predictor of recur-
rence.  
  Barnes [54]  2006  161  Lumpectomy—103; 
Mastectomy—47; 
Information una-
vailable for 11 pa-
tients. No infor-
mation available on 
XRT 
Not 
pro-
vided 
Unknown  Yes   In the multivariate analysis, Ki-67 
was an independent predictor of 
recurrence (OR: 1.03, 95% CI: 
1.00–1.06; P=0.006). 
  Gauthier 
[45] 
2007  70  Patients underwent 
definitive surgery 
for DCIS, but no 
details were pro-
vided  
Not 
pro-
vided 
Unknown  Yes (as an 
independent 
factor and 
combined 
with p16 
expression 
and COX-2 
expression) 
High Ki-67 expression was an 
independent predictor of recur-
rence (HR: 2.7, 95% CI: 1.2–5.9). In 
addition, patients with recurrence 
were more likely than patients 
without recurrence to have the 
combination of high Ki-67, high 
p16, and high COX-2 expression. 
  Altintas [15]  2009  159  Lumpectomy—112; 
mastectomy—45 
Information una-
vailable for 2 pa-
tients. No infor-
mation available on 
XRT 
54  No  No  The investigators concluded that 
the biological marker, Ki67, is not 
an independent predictor of re-
currence. 
  Kerlikow-
ske [24] 
2010  329 
(Controls 
with no re-
currence, 186; 
All patients were 
treated with lum-
pectomy alone 
98  No  Yes   In the univariate analysis, patients 
with invasive recurrence were 
more likely than those without 
recurrence to exhibit the pheno-Journal of Cancer 2011, 2 
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cases with 
invasive re-
currence, 72; 
cases with 
DCIS recur-
rence, 71) 
type p16+COX-2+Ki-67+ or 
p16+Ki-67+. Ki-67 was individually 
associated with DCIS recurrence. 
In addition, patients with DCIS 
recurrence were more likely to 
have ER-Ki-67+ or 
p16+COX-2-Ki-67+ disease than 
were patients without recurrence. 
In the multivariate analysis, the 
phenotype p16+COX-2+Ki-67+ was 
a strong predictor of invasive 
recurrence (HR: 2.2; 95% CI: 
1.1-4.5). Phenotypes 
p16+COX-2+Ki-67+ (HR: 3.7; 95% 
CI: 1.7-7.9) and ER- HER2+Ki-67+ 
(HR: 5.8, 95% CI: 2.4-14) were 
strong predictors of DCIS recur-
rence. 
Cell Cycle Regulation and Apoptotic Markers 
cyclin D1 
  Jirström 
[42] 
2003  177  Lumpectomy 
without XRT—64; 
Lumpectomy with 
XRT—113 
63  No  Yes  The investigators reported cyclin 
D1 expression to be strongly and 
inversely related with risk of ipsi-
lateral local recurrence.  
  Chasle [38]  2003  50  All patients under-
went lumpectomy 
followed by XRT 
Un-
known 
No  No   Cyclin D1 was not a predictor of 
recurrence in either univariate or 
multivariate analysis. 
  de Roos [43]  2007  87   Lumpectomy—39; 
Mastectomy—48 
(21 patients re-
ceived XRT) 
49.8  No  No  Cyclin D1 was not associated with 
disease recurrence in either uni-
variate or multivariate analysis. 
  Millar [31]  2007  60  Lumpectomy with 
or without XRT—56 
(51 received XRT); 
Mastectomy with-
out XRT—4 
98  No  No  In the univariate analysis con-
ducted with clinicopathological 
parameters, cyclin D1 was not 
associated with disease recurrence. 
  Kulkarni 
[21] 
2008  69  Lumpectomy 
without XRT—26; 
Lumpectomy with 
XRT—43 
Mean 
time to 
recur-
rence: 
38.5 
Yes  No  The investigators concluded that 
the biological marker, cyclin D1, is 
not an independent predictor of 
recurrence. 
cyclin A 
  Chasle [38]  2003  50  All patients under-
went lumpectomy 
followed by XRT 
Un-
known 
No  Yes (when 
combined 
with Ki-67) 
A global proliferation factor (GPF) 
was calculated that was a sum of 
Ki-67 and cyclin A. In the univari-
ate and multivariate analyses, GPF 
was an independent predictor of 
recurrence. 
  Millar [31]  2007  60  Lumpectomy with 
or without XRT—56 
(51 received XRT); 
Mastectomy with-
out XRT—4 
98  No  No  In the univariate analysis con-
ducted with clinicopathological 
parameters, cyclin A was not as-
sociated with disease recurrence. 
cyclin E 
  Jirström 
[42]  
2003  177  Lumpectomy 
without XRT—64; 
Lumpectomy with 
XRT—113 
63  No  No  The investigators concluded that 
the biological marker, cyclin E, is 
not an independent risk factor for 
recurrence. 
p16 
  Jirström 
[42]  
2003  177  Lumpectomy 
without XRT—64; 
Lumpectomy with 
XRT—113 
63  No  No  The investigators concluded that 
the biological marker, p16, is not 
an independent risk factor for 
recurrence. 
  Gauthier 
[45] 
2007  70  Patients underwent 
definitive surgery 
for DCIS, but no 
details were pro-
vided  
Not 
pro-
vided 
Unknown  Yes (when 
combined 
with high 
COX-2 ex-
pression and 
high Ki-67 
expression) 
Patients with recurrence were 
more likely than patients without 
recurrence to have the combina-
tion of high Ki-67, high p16, and 
high COX-2 expression. 
  Kerlikow-
ske [24] 
2010  329 
(Controls 
with no re-
currence, 186; 
cases with 
All patients were 
treated with lum-
pectomy alone 
98  No  Yes  In the univariate analysis, patients 
with invasive recurrence were 
more likely than those without 
recurrence to have p16-positive 
disease (57% vs. 30%). p16 positiv-Journal of Cancer 2011, 2 
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invasive re-
currence, 72; 
cases with 
DCIS recur-
rence, 71)329 
patients 
ity combined with Ki-67 positivity 
and COX-2 positivity was also 
associated with invasive recur-
rence. p16 was individually asso-
ciated with invasive recurrence. In 
addition, p16 positivity combined 
with Ki-67 positivity and COX-2 
negativity was associated with 
DCIS recurrence. In the multivari-
ate analysis, the phenotype 
p16+COX-2+Ki-67+ was a strong 
predictor of invasive recurrence 
(HR: 2.2; 95% CI: 1.1-4.5). Also, the 
phenotype p16+COX-2-Ki-67+ was 
a strong predictor of DCIS recur-
rence (HR: 3.7; 95% CI: 2.4-14). 
p21                 
  Provenzano 
[22] 
2003  95   Lumpectomy 
without XRT—85; 
Lumpectomy with 
XRT—10 
101  Yes  Yes  Patients with local-regional recur-
rence were more likely than those 
without recurrence to have 
p21-positive disease (54% vs. 15%; 
OR: 6.0; P=0.01). p21 positivity 
was individually associated with 
recurrence. According to the mul-
tiple conditional logistic regression 
analysis, p21 expression was an 
independent predictor of recur-
rence (OR range: 4.31–6.54). 
  Chasle [38]  2003  50  All patients under-
went lumpectomy 
followed by XRT 
Un-
known 
No  No  According to univariate and mul-
tivariate analyses, p21 was not 
observed to be an independent 
predictor of recurrence. 
  Cornfield 
[46] 
2004  151  All patients were 
treated with lum-
pectomy alone 
65  No  No  p21 was not associated with dis-
ease recurrence in either univari-
ate or multivariate analysis. 
  Kulkarni 
[21] 
2008  69  Lumpectomy 
without XRT—26; 
Lumpectomy with 
XRT—43 
Mean 
time to 
recur-
rence: 
38.5 
Yes  No  The investigators concluded that 
the biological marker, p21, is not 
an independent predictor of re-
currence. 
p27                 
  Millar [31]  2007  60  Lumpectomy with 
or without XRT—56 
(51 received XRT); 
Mastectomy with-
out XRT—4 
98  No  No  In the univariate analysis con-
ducted with clinicopathological 
parameters, p27 was not associat-
ed with disease recurrence. 
  Jirström 
[42]  
2003  177  Lumpectomy 
without XRT—64; 
Lumpectomy with 
XRT—113 
63  No  No  The investigators concluded that 
the biological marker, p27, is not 
an independent risk factor for 
recurrence. 
p53                 
  Hieken [48]  2001  103  Lumpectomy 
without XRT—34; 
Lumpectomy with 
XRT—41; Mastec-
tomy—28 
58 
(mean 
fol-
low-up 
time) 
Yes  Yes  p53 was expressed in 63% of pa-
tients with recurrence and 24% of 
patients without recurrence 
(P=0.03). The investigators con-
cluded that strong p53 expression 
is associated with ipsilateral tumor 
recurrence. 
  Ringberg 
[16] 
2001  187  Lumpectomy with 
XRT—66; Lumpec-
tomy without 
XRT—121 
62  No  Yes (when 
combined 
with other 
biological 
markers) 
The investigators evaluated a cell 
biological index (CBI-7) that in-
cluded ER and PR negativity, 
overexpression of HER2, low Bcl-2 
expression, accumulation of p53, 
nondiploidy, and high Ki-67 ex-
pression. High p53 expression 
combined with all those markers 
was a strong predictor of recur-
rence (RR: 1.3; 95% CI: 1.0-1.6; 
P=0.051). 
  Provenzano 
[22] 
2003  95 (53 cases 
and 42 con-
trols) 
Lumpectomy 
without XRT—85; 
Lumpectomy with 
XRT—10 
101  Yes  No  The investigators did not find p53 
to be associated with disease re-
currence. 
  Chasle [38]  2003  50  All patients under-
went lumpectomy 
followed by XRT 
Un-
known 
No  No  p53 was not an independent pre-
dictor of recurrence in either uni-
variate or multivariate analysis. Journal of Cancer 2011, 2 
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  Cornfield 
[46] 
2004  151  All patients were 
treated with lum-
pectomy without 
XRT 
 
65  No  No  p53 was not associated with dis-
ease recurrence in either univari-
ate or multivariate analysis. 
  Roka [23]  2004  190  Lumpectomy 
without XRT—33; 
Lumpectomy with 
XRT—99; Mastec-
tomy and XRT—58 
61.6  Yes  No  The investigators did not find p53 
to be an independent predictor of 
disease recurrence. 
  Kepple [59]  2006  94  Lumpectomy 
without XRT—17; 
Lumpectomy with 
XRT—20; Mastec-
tomy—57 
48 
months 
Yes  Unknown  Difficult to assess effect. Only 37 
patients underwent lumpectomy, 
and there were only 4 recurrences 
in that group. Some of those 37 
patients received radiotherapy and 
some did not. 
  de Roos [43]  2007  87  Lumpectomy—39; 
Mastectomy—48 
(21 patients re-
ceived XRT) 
49.8  No  Yes  p53 was an independent predictor 
of disease recurrence in multivari-
ate (HR: 3.0, 95% CI: 1.1-8.2, 
P=0.036) and univariate (HR: 3.5, 
95% CI: 1.3-9.3, P=0.014) analyses. 
  Kulkarni 
[21] 
2008  69  Lumpectomy 
without XRT—26; 
Lumpectomy with 
XRT—43 
Mean 
time to 
recur-
rence: 
38.5 
Yes  No  The investigators concluded that 
the biological marker, p53, is not 
an independent predictor of re-
currence. 
  Kerlikow-
ske [24] 
2010  329 
(Controls 
with no re-
currence, 186; 
cases with 
invasive re-
currence, 72; 
cases with 
DCIS recur-
rence, 71) 
All patients were 
treated with lum-
pectomy alone 
98  No  No  p53 was not associated with inva-
sive or DCIS recurrence either 
individually or when combined 
with other phenotypes. 
Bcl-2                 
  Ringberg 
[16] 
2001  187  Lumpectomy with 
XRT—66; Lumpec-
tomy without 
XRT—121 
62  No  Yes (when 
combined 
with other 
biological 
markers) 
The investigators evaluated a cell 
biological index (CBI-7) that in-
cluded ER and PR negativity, 
overexpression of HER2, low Bcl-2 
expression, accumulation of p53, 
nondiploidy, and high Ki-67 ex-
pression. Low Bcl-2 expression 
combined with all those markers 
was a strong predictor of recur-
rence (RR: 1.3; 95% CI: 1.0-1.6; 
P=0.051). 
  Provenzano 
[22]  
2003  95   Lumpectomy 
without XRT—85; 
Lumpectomy with 
XRT—10 
101  Yes  Yes  Patients with local-regional recur-
rence were more likely than those 
without recurrence to have 
Bcl-2-negative disease (66% vs. 
26%; P=0.003; OR: 0.18). 
  Cornfield 
[46] 
2004  151  All patients were 
treated with lum-
pectomy alone 
65  No  No  Bcl-2 was not associated with 
disease recurrence in either uni-
variate or multivariate analysis. 
Survivin                 
  Barnes [54]  2006  161  Lumpectomy—103; 
Mastectomy—47; 
Information una-
vailable for 11 pa-
tients. No infor-
mation available on 
XRT 
Not 
pro-
vided 
Unknown  Yes (not as an 
independent 
factor, but 
when com-
bined with 
COX-2 ex-
pression) 
Patients with recurrence were 
more likely than those without 
recurrence to have co-expression 
of COX-2 and cytoplasmic sur-
vivin (70% vs. 41%; P=0.013). 
c-myc                 
  Altintas [15]  2009  159  Lumpectomy—112; 
Mastectomy—45 
Information una-
vailable for 2 pa-
tients. No infor-
mation available on 
XRT 
54  No  No  The investigators concluded that 
the biological marker, c-myc, is not 
an independent predictor of re-
currence. 
Angiogenesis-related proteins 
VEGF 
  Hieken [48]  2001  103  Lumpectomy  58  Yes  No  The investigators did not find Journal of Cancer 2011, 2 
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without XRT—34; 
Lumpectomy with 
XRT—41; Mastec-
tomy—28 
(mean 
fol-
low-up 
time) 
VEGF to be an independent pre-
dictor of disease recurrence. 
Epidermal Growth Factor Receptor Family  
HER1                 
  Barnes [35]  2005  129  Lumpectomy—89; 
Mastectomy—40 
(8 patients received 
XRT) 
5 years  Unknown  No  The investigators concluded that 
the biological marker, HER1, is not 
an independent predictor of re-
currence. 
  Altintas [15]  2009  159  Lumpectomy—112; 
mastectomy—45 
Information una-
vailable for 2 pa-
tients. No infor-
mation on XRT 
54  No  No  The investigators concluded that 
the biological marker, HER1, is not 
an independent predictor of re-
currence. 
HER2                 
  Ringberg 
[16] 
2001  187  Lumpectomy with 
XRT—66; Lumpec-
tomy without 
XRT—121 
62  No  Yes (when 
combined 
with other 
biological 
markers) 
The investigators evaluated a cell 
biological index (CBI-7) that in-
cluded ER and PR negativity, 
overexpression of HER2, low Bcl-2 
expression, accumulation of p53, 
nondiploidy, and high Ki-67 ex-
pression. HER2 positivity com-
bined with all those markers was a 
strong predictor of recurrence (RR: 
1.3; 95% CI: 1.0-1.6; P=0.051). 
  Provenzano 
[22] 
2003  95   Lumpectomy 
without XRT—85; 
Lumpectomy with 
XRT—10 
101  Yes  Yes  Patients with local-regional recur-
rence were more likely than those 
without recurrence to have 
HER2-positive disease (41% vs. 
12%; OR: 5.0; P=0.008).  
  Roka [23]  2004  190  Lumpectomy 
without XRT—33; 
Lumpectomy with 
XRT—99; Mastec-
tomy with XRT—58 
61.6  Yes  No  The investigators did not find 
HER2 to be an independent pre-
dictor of disease recurrence. 
  Cornfield 
[46] 
2004  151  All patients were 
treated with lum-
pectomy alone 
65  No  No  HER2 was not associated with 
disease recurrence in either uni-
variate or multivariate analysis. 
  Barnes [35]  2005  129  Lumpectomy—89; 
Mastectomy—40 
(8 patients received 
XRT) 
5 years  Unknown  No  The investigators concluded that 
the biological marker, HER2, is not 
an independent predictor of re-
currence. 
  Barnes [54]  2006  161  Lumpectomy—103; 
Mastectomy—47; 
Information una-
vailable for 11 pa-
tients. No infor-
mation available on 
XRT 
Not 
pro-
vided 
Unknown  No  HER2 was not associated with 
disease recurrence in multivariate 
analysis. 
  Kepple [59]  2006  94  Lumpectomy 
without XRT—17; 
Lumpectomy with 
XRT—20; Mastec-
tomy—57 
48 
months 
Yes  Unknown  Difficult to assess effect. Only 37 
patients underwent lumpectomy, 
and there were only 4 recurrences 
in that group. Some of those 37 
patients received radiotherapy and 
some did not. 
  de Roos [43]  2007  87  Lumpectomy—39; 
Mastectomy—48 
(21 patients re-
ceived XRT) 
49.8  No  No  HER2 overexpression was associ-
ated with recurrence in univariate 
analysis (HR: 3.1, 95% CI: 1.1-8.7; 
P=0.032). However, multivariate 
analysis did not show HER2 
overexpression to be an inde-
pendent predictor of recurrence. 
  Kulkarni 
[21] 
2008  69  Lumpectomy 
without XRT—26; 
Lumpectomy with 
XRT—43 
Mean 
time to 
recur-
rence: 
38.5 
Yes  No  The investigators concluded that 
the biological marker, HER2, is not 
an independent predictor of re-
currence. 
  Altintas [15]  2009  159  Lumpectomy—112; 
mastectomy—45 
Information una-
vailable for 2 pa-
tients. No infor-
mation available on 
54  No  No  The investigators concluded that 
the biological marker, HER2, is not 
an independent predictor of re-
currence. Journal of Cancer 2011, 2 
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XRT 
  Stackievicz 
[74] 
2010  84  Lumpectomy—80 
(43 patients re-
ceived XRT); Mas-
tectomy—4 
94.8  Yes  No  The investigators concluded that 
the biological marker, HER2, is not 
an independent risk factor for 
recurrence. 
  Kerlikow-
ske [24] 
2010  329 
(Controls  
with no re-
currence, 186; 
cases with 
invasive re-
currence, 72; 
cases with 
DCIS recur-
rence, 71) 
All patients were 
treated with lum-
pectomy alone 
98  No  Yes  In the univariate analysis, patients 
with DCIS recurrence were more 
likely than patients without re-
currence to have HER2-positive 
disease (30% vs. 13%). HER2 was 
individually associated with DCIS 
recurrence. Also, patients with 
DCIS recurrence were more likely 
than patients without recurrence 
to exhibit the ER-HER2+ phenotype 
(19% vs. 6.4%). In addition, a mul-
tivariate analysis showed that the 
phenotype ER-HER2+Ki-67+ was a 
strong predictor of subsequent 
DCIS recurrence (OR: 5.8; 95% CI: 
2.4-14). 
  Zhou [25]  2010  392  Lumpectomy 
without XRT—158; 
Lumpectomy with 
XRT—140; Mastec-
tomy —94 
97.5  No  No  The investigators looked at ba-
sal-like tumors (tumors negative 
for ER, PR, and HER2). In the 
univariate and multivariate anal-
yses, basal-like DCIS was associ-
ated with a higher risk of local 
recurrence (HR: 1.7) than 
non-basal-like DCIS (HR: 1.8). 
However, the difference was not 
statistically significant. (Note: The 
authors do not state in the paper 
how many patients with basal-like 
DCIS developed a recur-
rence—they only report HRs in the 
tables.) 
  Witkiewicz 
[61] 
2010  97  All patients under-
went lumpectomy 
(no information was 
available about 
XRT) 
110.8  No  No  The investigators did not find 
HER2 to be an independent pre-
dictor of recurrence. 
  Holmes [58]  2011  141  All patients under-
went lumpectomy 
alone 
125  No  Yes  Univariate analysis with respect to 
time to recurrence found HER2 
overexpression to be associated 
with local recurrence (P=0.028). In 
the multivariate analysis, HER2 
overexpression was an independ-
ent predictor of disease recurrence 
(HR: 1.82, 95% CI: 1.03-3.22, 
P=0.041). 
HER3 
  Barnes [35]  2005  129  Lumpectomy—89; 
Mastectomy—40 
(8 patients received 
XRT) 
5 years  Unknown  No  The investigators concluded that 
the biological marker, HER3, is not 
an independent predictor of re-
currence. 
  Altintas [15]  2009  159  Lumpectomy—112; 
mastectomy—45 
Information una-
vailable for 2 pa-
tients. No infor-
mation on XRT 
54  No  No  The investigators concluded that 
the biological marker, HER3, is not 
an independent predictor of re-
currence. 
HER4 
  Barnes [35]  2005  129  Lumpectomy—89; 
Mastectomy—40 
(8 patients received 
XRT) 
5 years  Unknown  Yes  The investigators concluded that 
HER4 expression is an independ-
ent predictor of a reduced risk of 
recurrence (OR: 0.69, 95% CI: 
0.48-0.98, P=0.038). 
  Altintas [15]  2009  159  Lumpectomy—112; 
mastectomy—45 
Information una-
vailable for 2 pa-
tients. No infor-
mation on XRT 
54  No  No  The investigators concluded that 
the biological marker, HER4, is not 
an independent predictor of re-
currence. 
Extracellular matrix-related proteins           
CD10                 
  Toussaint  2010  154  Surgical infor- 6 years  Yes   Yes  According to the multivariate Journal of Cancer 2011, 2 
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[60]  mation was report-
ed according to 
VNPI. 58% of pa-
tients with low 
VNPI were treated 
with lumpectomy 
alone; 41% of those 
with intermediate 
VNPI received XRT 
following lumpec-
tomy; 81% of pa-
tients with high 
VNPI underwent 
mastectomy 
analysis, CD10 was an independ-
ent predictor of recurrence. Pa-
tients with low CD10 expression 
were more likely than those with 
high CD10 expression to develop 
recurrence (HR: 2.39, 95% CI: 
1.52-3.76, P=0.001). 
  Witkiewicz 
[61] 
2010  97  All patients under-
went lumpectomy 
(no information was 
available about 
XRT) 
110.8  No  Yes  In the multivariate analysis, CD10 
was an independent predictor of 
recurrence. Patients with recur-
rence were more likely than those 
without recurrence to exhibit 
strong stromal CD10 expression 
(OR: 10.2, 95% CI: 2.7, 37.7). 
SPARC 
  Witkiewicz 
[61] 
2010  97  All patients under-
went lumpectomy 
(no information was 
available about 
XRT) 
110.8  No  Yes  In the multivariate analysis, 
SPARC was an independent pre-
dictor of recurrence. Patients with 
recurrence were more likely than 
those without recurrence to exhibit 
strong stromal SPARC expression 
(OR: 3.9, 95% CI: 1.1, 14.3). 
COX-2                 
  Barnes [54]  2006  161  Lumpectomy—103; 
Mastectomy—47; 
Information una-
vailable for 11 pa-
tients. No infor-
mation available on 
XRT 
Not 
pro-
vided 
Unknown  Yes (as an 
independent 
factor and in 
combination 
with survivin) 
In the multivariate analysis, 
COX-2 was an independent pre-
dictor of recurrence. In addition, 
patients with recurrence were 
more likely than those without 
recurrence to have co-expression 
of COX-2 and cytoplasmic sur-
vivin compared to patients with-
out recurrences co-expressing both 
proteins (70% vs. 41%; P=0.013). 
  Gauthier 
[45] 
2007  70  Patients underwent 
definitive surgery 
for DCIS, but no 
details were pro-
vided  
Not 
pro-
vided 
Unknown  Yes (when 
combined 
with high p16 
expression 
and high 
Ki-67 expres-
sion) 
COX-2 was not an independent 
predictor of recurrence. However, 
patients with recurrence were 
more likely than those without 
recurrence to express the combi-
nation of high Ki-67, high p16, and 
high COX-2 expression. 
  Kulkarni 
[21] 
2008  69  Lumpectomy 
without XRT—26; 
Lumpectomy with 
XRT—43 
Mean 
time to 
recur-
rence: 
38.5 
Yes  Yes  In the multivariate analysis, 
COX-2 expression was signifi-
cantly associated with increased 
risk of recurrence (OR: 7.89; 95% 
CI 1.7-36.2). 
  Kerlikow-
ske [24] 
2010  329 
(Controls 
with no re-
currence, 186; 
cases with 
invasive re-
currence, 72; 
cases with 
DCIS recur-
rence, 71) 
All patients were 
treated with lum-
pectomy alone 
98  No  Yes (in com-
bination with 
other mark-
ers) 
In the univariate analysis, patients 
with invasive recurrence were 
more likely than those without 
recurrence to exhibit the pheno-
type p16+COX-2+Ki-67+ (23% vs. 
8.5%). Patients with DCIS recur-
rence were more likely than those 
without a recurrence to exhibit the 
phenotype p16+COX-2-Ki-67+ (19% 
vs. 2.6%). COX-2 was not individ-
ually associated with recurrence. 
In the multivariate analysis the 
phenotype p16+COX-2+Ki-67+ was 
a strong predictor of invasive 
recurrence (HR: 2.2; 95% CI: 
1.1-4.5). Another phenotype, 
p16+COX-2-Ki-67+, was a strong 
predictor of DCIS recurrence (HR: 
3.7; 95% CI: 1.7-7.9). 
XRT, radiotherapy; VNPI, Van Nuys Prognostic Index. 
 
 
 